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Abbreviations: CK, creatine kinase; CNBP, cellular nucleic acid binding protein; CUG-BP, CUG-binding protein; DM1, 
myotonic dystrophy type 1; DM2, myotonic dystrophy type 2; DMPK, myotonic dystrophy protein kinase; ECG, elec-
trocardiography; EMG, electromyography; ENMC, European Neuromuscular Centre; FEES, fiberoptic endoscopic 
evaluation of swallowing; FMS, fibromyalgia syndrome; MBNL, muscle blind-like protein; NSAID, non-steroidal an-
ti-inflammatory drugs; PDM, proximal myotonic dystrophy; PROMM, proximal myotonic myopathy; QST, quantitative 
sensory testing; SMN1, survival motor neuron; SS, symptom severity scale; TSH, thyroid stimulating hormone; WPI, 
widespread pain index; ZNF9, zinc finger protein 9.
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MYOTONIC DISORDERS
Myotonia is a delayed relaxation of a muscle after contraction (Figure 1.1). It is both a symptom 
and sign that occurs in a selection of neuromuscular disorders. These myotonic disorders can 
be divided into the nondystrophic myotonic disorders and dystrophic myotonic disorders [1]. 
Muscular dystrophies are a heterogeneous group of genetic disorders with progressive 
muscle weakness and degeneration of the skeletal muscles [2]. 
Nondystrophic myotonic disorders present with electrical and clinical myotonia due 
to ion channel dysfunction and generally do not present with prominent muscle weakness, 
atrophy, and abnormal histopathology [3,4]. They include both chloride and sodium channel 
disorders. Dystrophic myotonic disorders include myotonic dystrophy type 1 (DM1), a well-
known and relatively common autosomal dominant multisystem disorder, and myotonic 
dystrophy type 2 (DM2), a rare autosomal dominant multisystem disorder with a particularly 
variable phenotype. They both have some of the most diverse, disease related symptoms 
known in medicine [5]. In this thesis epidemiological aspects of DM2 and several of its 
multisystem aspects will be designated.
Figure 1.1 Myotonia
Myotonia: a delay in muscle relaxation after contraction.
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MYOTONIC DYSTROPHY TYPE 2
DM2 is a rather new entity. The first reports were described in 1994 by Ricker et al. and 
Thornton et al. [6,7]. They described an autosomal dominant multisystem disorder with muscle 
weakness, myotonia and early-onset cataract, similar to myotonic dystrophy type 1 (DM1), 
but without the characteristic genetic defect. The disease was named proximal myotonic 
myopathy (PROMM) because of the preferential proximal muscle weakness. An important 
complaint of patients with PROMM was stiffness and a peculiar muscle pain, rather than 
weakness, in contrast to patients with DM1 [8]. In the following years, several case reports with 
similar clinical features were described and called PROMM, proximal myotonic dystrophy 
(PDM) and type 2 myotonic dystrophy [8-12]. In 2001, an unstable CCTG expansion in intron 1 
of the CNBP gene, mapped to chromosome 3q21.3, was discovered in all patients with the 
PROMM/PDM/DM2 phenotypes [13-15]. From that time on, the disorder was called myotonic 
dystrophy type 2 (DM2). In 2004, the first Dutch family with DM2 was reported [16].
CLINICAL FEATURES
The symptoms of DM2 typically present in adult life. The mean age of onset is between 
the third and fourth decade, with a broad range [17,18]. DM2 is a multisystem disorder with 
involvement of many different organs and systems. The clinical features are highly variable 
interindividually, ranging from paucisymptomatic elderly patients to younger aged patients 
with multisystem involvement who are wheelchair bound due to proximal leg weakness. 
Core clinical features of DM2 are progressive muscle weakness, muscle pain, myotonia 
and early-onset cataract [17]. Prognosis and life expectancy are rather favourable, although 
7-10% of patients will lose the ability to walk because of their muscle weakness [19,20]. Cardiac 
arrhythmias may be a cause of premature death [21]. The most common initial symptom is 
proximal muscle weakness, followed by myalgia and myotonia [18,20,22].
Muscle symptoms and signs
Muscle weakness, pain, stiffness and myotonia are the most common reported symptoms 
in patients with DM2 [18,20,22]. Muscle weakness is typically present in the proximal muscles, 
predominantly in the legs. In a cohort of 234 patients with DM2, the most frequently involved 
muscles were the thigh and hip flexor and extensor muscles, neck flexors, elbow extensors, 
and thumb and deep finger flexors [17]. Prominent muscle weakness of respiratory, bulbar and 
facial muscles is typically absent or only mild [17,19]. Muscle atrophy is relatively mild or absent, 
while calf hypertrophy may be present [17,19]. 
In the largest reports to date, myotonia is clinically present in 41% to 75% of patients 
with DM2 [17,20,22]. Myotonic discharges are present on needle electromyography (EMG) in 
80-90% [17,20,22,23]. Logigian et al. examined 17 patients with DM2 who all exhibited grip or 
percussion myotonia extensively with needle EMG and reported myotonic discharges in all 
patients, most prominent in the distal limb muscles, with a prevalence of 100% in the tibialis 
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anterior muscle [24]. The percentage of myotonic discharges declined in a distal to proximal 
gradient in DM2, but less steep than in DM1.
Pain is an important and disabling feature in patients with DM2, with a reported lifetime 
prevalence of 76% and a negative impact on quality of life [25-28]. Up to a third of patients 
reported pain as the most disabling feature [25]. The pain experienced by patients with DM2 
shows important similarities to that of the chronic musculoskeletal pain experienced by 
patients with fibromyalgia syndrome (FMS) [19,29]. 
HyperCKemia has been described as the sole manifestation of DM2 in a case report [30]. 
Serum creatine kinase (CK) is often mild to moderately elevated in patients with DM2 with a 
prevalence of hyperCKemia of 48-78% [22,31]. 
Eyes
Posterior subcapsular iridescent cataract is frequently present in patients with DM2, and 
typically develops in the third to fifth decades of life, with a prevalence of 50-75% [17,20,22]. 
Early-onset cataract is defined as an onset of cataract before the age of 50 years, and should 
alert the clinician to consider myotonic dystrophy [32,33]. In a recent retrospective study of 28 
patients with DM2, 32% were formerly diagnosed with early-onset cataract [34]. None of them 
were referred for neuromuscular evaluation; median time between onset of cataract and 
DM2 diagnosis was 16 years. In another cohort, 150 subjects with cataract before the age of 
55 years were genetically tested for DM2, 11 of them were found to have DM2 [33]. 
Heart
Cardiac abnormalities were reported in 39.5% of 38 patients with DM2, significantly more 
frequent than in healthy controls with a similar distribution of atherosclerotic risk factors 
[35]. Fourteen patients had conductive defects, six patients showed left ventriculair systolic 
dysfunction and supraventricular arrhythmias were present in six patients. Cardiomyopathy 
has also been described; Ricker et al. reported six males having heart transplantation before 
DM2 was diagnosed in a cohort of 480 patients [19,36]. Four patients with a sudden cardiac 
death were reported in the same cohort [19]. Sansone et al. reported 104 patients with DM2; 
10% had a prolonged PR-interval and 17% a prolonged QRS duration on electrocardiography, 
significantly less than in DM1 [37]. Six patients with DM2 required a pacemaker. 
Endocrine system
There is an increased frequency of insulin insensitivity and diabetes mellitus in patients 
with DM2, and hypogonadism resulting in male infertility [17,38]. There is also an increased 
prevalence of thyroid dysfunction (mainly hypothyroidism), with a reported frequency as 
high as 32% in a large cohort of 307 patients [20].  Passeri et al. reported hyperparathyroidism 
in up to 20% of patients with DM2 [38]. Another frequently reported symptom is excessive 
sweating [12,22].
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Central nervous system
The educational level of patients with DM2 is within the normal distribution, intelligence 
quotient is not affected [19,39]. However, neuropsychological examination showed significant 
lower scores for frontal lobe function and neuropsychiatric interviews demonstrated an 
avoidant personality trait in a cohort of 19 patients with DM2 compared to healthy controls, 
albeit to a lesser extent than in DM1 [39]. Similar observations were more recently reported 
with abnormal executive functioning in 50% of patients with DM2 on neuropsychologic 
examination [40]. Minnerop et al. reported the presence of white matter involvement in 
patients with DM2, predominantly in the frontal lobe, but to a lesser extent than in DM1 [41]. 
Sleep disturbances in patients with DM2 include increased sleep latency associated with 
nocturnal pain resulting in a bad sleep quality, and also restless legs syndrome and sleep 
apnea have been described [42,43]. 
Other
Many other comorbidities are reported to be associated with DM2. A high incidence 
of dyslipidemia has been described [20,22]. Also, a strong association between DM2 and 
autoimmune diseases has been reported [44]. Patients with DM2 appear to have a higher risk of 
developing cancer according to two retrospective studies [45,46]. Extrapiramidal manifestations 
including a postural tremor have also been described [22]. Several gastrointestinal symptoms 
including dysphagia and constipation were already mentioned in the first European 
Neuromuscular Centre (ENMC) International Workshop Report on PROMM as supportive 
findings for the diagnosis PROMM [47]. However, this expert opinion has not been corroborated 
with clinical research. Sensorineural hearing impairment has been reported in several case 
reports of PROMM, including in different familial cases, but again has not been studied 
systematically [7,11,12,48-51]. In DM1 there is well documented increased anaesthetic risk, mainly 
concerning respiratory problems. The risk of perioperative complications is reported to be 
rather low in DM2, probably related to the fact that the respiratory tract is involved to a lesser 
extent [52]. However, good clinical perioperative monitoring is strongly recommended.
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ILLUSTRATION OF THE HIGHLY VARIABLE DM2 PHENOTYPE 
Case 1
A 73-year old man presented with difficulty in walking since one year. He complained of 
tingling of his feet, back pain, and was unable to climb stairs. He had no myalgia, cramps 
or stiffness and no visual impairment. His medical history revealed rheumatoid arthritis, 
atrial fibrillation and severe hearing impairment. On neurologic examination, symmetrical 
distal sensory loss and areflexia of both feet were found, and a polyneuropathy was 
established with nerve conduction studies. He also had slight symmetrical proximal 
muscle weakness of the deltoideus and iliopsoas, but no clinical myotonia. The DM2 
mutation was analyzed because both his brother and sister were diagnosed with DM2, 
and he was found to have DM2 as well. Afterwards, bilateral cataract was diagnosed and 
he underwent surgery. In the following years, proximal muscle weakness became more 
apparent. At present, he is essentially wheelchair bounded at an age of 79 years old. 
Case 2
A 40-year old woman visited the outpatient department because she had pain in the back 
and diffuse myalgia for at least ten years. She also complained of progressive difficulty in 
cycling and climbing stairs, and told she let objects slip from her hands. Her complaints 
worsened with cold weather and she could not open her hands after washing them 
with cold water. Three years earlier, fibromyalgia syndrome was diagnosed. She had a 
blurred vision since she was 26 years of age and at the age of 38 she was diagnosed with 
cataract, now awaiting surgery. She was also known with hyperthyroidism. Neurological 
examination showed muscle weakness of the neck flexors and proximal muscles of 
the extremities, next to eyelid myotonia. Electromyography demonstrated myotonic 
discharges. Serum CK was 158 U/l. Both her sister and mother had similar complaints, 
including cataract. In 1999, the DM1 mutation appeared negative and she was diagnosed 
with the clinical diagnosis PROMM. In 2002, DM2 could be verified with DNA analysis.  
Case 3
A 55-year old woman complained of leg weakness since the age of 8 years. She had 
progressive difficulty in climbing stairs and rising from a chair. Her mother and sister 
had similar complaints. Neurologic examination demonstrated muscle weakness of 
the neck flexors, triceps and hip flexors. Serum CK was 261 U/l, extensive laboratory 
examination was otherwise normal. Electromyography showed fibrillation potentials 
in the gastrocnemius and tibialis anterior muscles bilaterally and left rectus femoris 
and interosseus dorsalis muscles, but no myotonic discharges or myopathic changes. 
Pompe disease was genetically excluded and no genetic defect of the SMN1 gene was 
demonstrated. A motor neuron disease was suspected, however with further extensive 
DNA analysis, she was diagnosed with DM2.
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MYOTONIC DYSTROPHY TYPE 2 COMPARED TO MYOTONIC DYSTROPHY TYPE 1
Myotonic dystrophy type 1 (DM1) is the most common muscular dystrophy in adults, 
caused by a CTG repeat expansion in the DMPK gene on chromosome 19q13.3 [53]. DM1 is 
a multisystem disorder and shows many clinical similarities to DM2, including progressive 
muscle weakness, myotonia and early-onset cataract, but it shows many differences as well. 
There are four different forms of DM1: congenital, childhood-onset, adult-onset and late-
onset oligosymptomatic [5]; the adult-onset form being the most prevalent. In DM2 there are 
no distinct clinical subgroups. In DM1, the size of the repeat expansion is correlated with 
clinical severity and age of onset [54], while in DM2 the repeat expansion is very large and 
instable and not correlated with clinical features [55]. Anticipation, an increase of symptom 
severity and a younger age of onset in each consecutive generation, is a distinct feature 
of DM1, but exceptionally rare in DM2 [12,17,56]. The main clinical similarities and differences 
between DM2 and DM1 are shown in Table 1.1.
Figure 1.2 Multisystem involvement in DM2
Cataract
Cardiac arrythmias
Cardiomyopathy
Weakness
Myotonia
Pain
Autoimmune diseases
None or mild cognitive
dysfunction
White matter involvement
Thyroid dysfunction
Diabetes mellitus 
type 2 Male hypogonadism
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Table 1.1 Clinical similarities and differences between DM2 and DM1
Features DM2 DM1
Prevalence Unknown
Probably underreported
Geographical distribution
1:10.000
Most common adult 
muscular dystroph
Genetics
Inheritance
Chromosome
Locus
Anticipation
Congenital form
Autosomal dominant
3q21.3
DMPK
Exceptionally rare 
Absent
Autosomal dominant
19q13.3
CNBP
Present
Present
Muscles
   Weakness
   Respiratory weakness
   Facial and bulbar weakness
   Clinical myotonia
   EMG: myotonic discharges
   Pain
Mainly proximal
Exceptional
Usually absent
Variable, may be mild or absent
Usually present (80-90%)
Most disabling symptom in 
many patients
Mainly distal
Always (later) in adult-onset
Always (later)
Evident in adult-onset
Always present
Absent or moderate
   Serum creatine kinase Normal to moderate increase Normal to moderate 
increase
Eyes
   Early-onset cataract Often present Often present
Heart
   Cardiac arrhythmias
   Cardiomyopathy
Variable, absent to severe
Rare
Common
May be present
Endocrine system
   Diabetes mellitus type 2
   Hypogonadism
   Thyroid dysfunction
May be present
Common
Common
May be present
Common
Common 
Central nervous system
   Mental retardation 
   Cognitive dysfunction
   Sleep disturbances
Absent
Absent or mild
Bad sleep quality
Present in congenital and 
childhood-onset forms
Prominent
Excessive daytime 
sleepiness
Gastrointestinal system
   Dysphagia
   Abdominal pain
   Constipation and diarrhoea
   Anal incontinence
Only case reports
Unknown
Only case reports
Unknown
Common
Common
Common, mainly constipation
Common
Ears
   Hearing impairment Only case reports Common
Other features
   Autoimmune disorders
   Life expectancy
May be present
Normal range
Rare
Reduced (mean 53 years)
Abbreviations: DM2, myotonic dystrophy type 2; DM1, myotonic dystrophy type 1; EMG, electromyography; 
DMPK, myotonic dystrophy protein kinase; CNBP, cellular nucleic acid binding protein.
Features that warrant more research in red [5,17,20,22,32,44,57-59]
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PREVALENCE
The exact prevalence of DM2 is unknown and seems to vary geographically, probably due to 
a founder effect (Figure 1.3) [60]. In general, most reported patients with DM2 live in Europe. 
In Germany, the prevalence of DM2 might be as high as DM1, given the similar number of 
positive diagnostic tests for DM2 and DM1 annually [19]. The estimated prevalence in Germany 
is 1:20.000 and Suominen et al. reported an even higher prevalence in Finland of 1:2250 DM2 
mutations in 4500 healthy subjects [61,62]. In Italy, the prevalence of DM2 was reported to be 
ten times lower than DM1 [63]. DM2 seems to be extremely rare in Japan, and has not been 
reported in China and Sub-Saharan Africa [64,65]. 
In the Netherlands, in 2011 only 45 patients from 17 different families with genetically 
proven DM2 were known.
Figure 1.3 Geographic distribution of patients with DM2 throughout the world
Countries: Canada, USA, Suriname, UK, Norway, Sweden, Finland, The Netherlands, Belgium, France, Spain, 
Portugal, Germany, Switzerland, Italy, Malta, Poland, Czech Republic, Slovakia, Ukraine, Serbia, Greece, 
Morocco, Algeria, Lebanon, Afghanistan, India, Sri Lanka and Japan [13,14,65-69].
UNDERREPORTING
DM2 is particularly difficult to recognize. The average diagnostic delay (time between 
initial symptoms and diagnosis) in DM2 is 14 to 16 years [18,34]. The phenotype of DM2 is 
heterogeneous, with a wide variety of symptoms and a diverse age of onset. Moreover, the 
onset of DM2 is often rather atypical, frequently consisting of muscle pain and muscle stiffness 
[17,61]. Many patients with DM2 lack core clinical features at onset, like muscle weakness, 
myotonia and cataract, making DM2 a challenging diagnosis. Hilbert et al. reported that 50% 
of the registered patients with DM2 were the first member of their family to be diagnosed with 
DM2, a higher percentage than in DM1 patients (39%) [18]. This suggests that other affected 
DM2 family members show only mild or no symptoms, and are not diagnosed or perhaps 
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Figure 1.4 RNA model of pathogenesis in DM2 and DM1
Abbreviations: DM2, myotonic dystrophy type 2; DM1, myotonic dystrophy type 1; DMPK, myotonic dystrophy 
protein kinase; ZNF9, zinc finger protein 9; CUG-BP, CUG-binding protein; MBNL, muscle blind-like protein.
This figure demonstrates that RNA gain-of-function eventually leads to the multisystem features (reprinted with 
permission) [70].
misdiagnosed. Given the difficulties in diagnosing DM2 and unfamiliarity of clinicians with 
this disorder, it seems likely that DM2 is underdiagnosed and underreported.
GENETICS AND PATHOGENESIS
DM2 is caused by a CCTG repeat expansion of the CNBP gene (previously known as ZNF9 
gene) on chromosome 3q21.3 [13]. The expanded repeat length ranges from 75 to over 11.000 
units, is highly unstable and displays marked somatic mosaicism (a different repeat size in 
different cells). The repeat size seems to relate to the age of the patient, but not to the severity 
of the clinical features [12,17,55].
Both DM2 and DM1 are autosomal dominant multisystem disorders with many clinical 
similarities, and both are caused by a repeat instability in a noncoding part of a gene (on 
respectively chromosome 3 and 19). In both diseases, the pathogenesis can be explained by 
a toxic RNA gain-of-function mechanism (Figure 1.4). In DM2, expanded CCUG-containing 
transcripts accumulate in the cell nuclei as rubonuclear foci. This mutant RNA leads to 
deregulation and altered localization of several RNA  binding factors, including the CUG-
binding protein (CUG-BP) and muscle blind-like proteins (MBNLs) [70,71]. Both proteins play 
a role in affecting alternative splicing; changes in the regulation of these proteins may lead 
to abnormal splicing of downstream genes expressed in DM target tissues and to alternative 
splicing of other mRNA-transcripts [71].
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MANAGEMENT 
To date, no curative treatment for DM2 is available. However, many aspects of this 
multisystem genetic disorder deserve attention and symptomatic treatment, preferable 
in a multidisciplinary approach by a neurologist, rehabilitation specialist, cardiologist and 
ophthalmologist. In a few single cases successful treatment of pain has been described, 
using non-steroidal anti-inflammatory drugs (NSAIDs), carbamazepine, phenytoin, a 
short-term course of corticosteroid therapy, baclofen, tizanidine and gabapentin [61,72-74]. In 
general, the first choice for treatment of myotonia is mexiletine, although data supporting 
its effectiveness in DM2 are lacking [75,76]. Cataract may need conventional surgical treatment. 
Regular cardiologic examination is recommended, including electrocardiography (ECG), 24-h 
ambulatory ECG and echocardiography. Implantation of a pacemaker may be indicated in 
the case of rhythm abnormalities [35]. Another important element in the care of patients with 
DM2 is genetic counselling. Finally, good clinical perioperative monitoring is recommended, 
although the risk of perioperative complications is reported to be not substantially increased 
in DM2 [52]. 
FIBROMYALGIA SYNDROME
The pain experienced by patients with DM2 shows some striking clinical similarities to the 
pain experienced by patients with fibromyalgia syndrome (FMS) [19,29]. FMS is a common 
chronic disorder with widespread musculoskeletal pain, often accompanied by a number 
of associated symptoms such as fatigue, anxiety and mood disorders, sleep disturbances, 
gastrointestinal symptoms and headache [77,78]. The estimated prevalence is around 2% [78-80]. 
FMS can be diagnosed using the preliminary 2010 American college of Rheumatology 
(ACR) diagnostic criteria [81]. According to these criteria, the widespread pain index (WPI) 
and symptom severity scale (SS) are determined. WPI is the sum of the number of painful 
body areas in the last week, ranging from 0-19 (a higher score indicating more areas of pain). 
The sum of the severity of four items (fatigue, waking unrefreshed, presence of cognitive 
symptoms, and general somatic symptoms) is used to calculate the SS (total score 0-12, a 
higher score indicating more severe symptoms). The criteria for FMS are met if WPI ≥ 7 and SS 
≥ 5 or WPI 3–6 and SS ≥ 9, with a duration of symptoms of at least three months and exclusion 
of another diagnosis explaining the pain. However, in these criteria it is not specifically defined 
how to exclude alternative diagnoses. Numerous blood tests have been recommended to 
exclude other diagnoses in patients with FMS, including blood sedimentation rate, C-reactive 
protein, red and white cell blood count, creatine kinase (CK), calcium and thyroid-stimulating 
hormone (TSH) [82].
The understanding of the pathogenesis of FMS is evolving in the last decade, however 
it is still not entirely clarified. It is believed that altered central pain processing plays an 
important role [83]. Various factors probably play a role in the development of this pain 
amplifying process, including genetic components, psychosocial factors and emotional 
stress, and other pain generating conditions [78,83]. 
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DM2 AND FIBROMYALGIA SYNDROME 
Striking similarities between DM2 and FMS include widespread fluctuating pain, a high 
frequency of fatigue and reported gastrointestinal symptoms [19,78,84]. In 2011, 4.4% of the 
Dutch patients with DM2 were formerly diagnosed with FMS (unpublished data). In addition, 
a Finnish study reported that 2 out of 63 (3%) FMS patients turned out to have underlying DM2 
as the explanation for their complaints [29]. Table 1.2 shows the similarities and differences 
between DM2 and FMS.
Table 1.2 Clinical similarities and differences between DM2 and FMS
Features  DM2 FMS
Muscles
   Pain
   Muscle weakness
      localization
   Myotonia
   Serum CK
Widespread fluctuating pain
Usually present
Proximal muscles
Usually present
Normal to moderate increase
Widespread fluctuating pain
May be present
No specific pattern
Absent
Normal
Eyes
   Early-onset cataract Common Absent
Heart
   Cardiac arrhythmias May be present Absent
Central nervous system
   Fatigue
   Sleep disturbances
Usually present
Bad sleep quality
Restless legs syndrome
Present
Bad sleep quality
Nonrestorative sleep
Gastrointestinal system
   Gastrointestinal symptoms May be present Common
Other
   Mood disorder
   Headache
Unknown
Unknown
Common
Common
Abbreviations: DM2, myotonic dystrophy type 2; FMS, fibromyalgia syndrome; CK, creatine kinase
[17,19,20,22,27,29,35,37,77,78,85].
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AIMS AND OUTLINE OF THE THESIS
This introduction shows that myotonic dystrophy type 2 is a relatively new autosomal 
dominant inherited multisystem disorder, in which many organs are involved. DM2 is generally 
difficult to diagnose and probably underreported due to the highly variable phenotype, 
the often atypical symptoms at onset and the supposed unfamiliarity of clinicians with the 
disorder. The aim of this thesis was to broaden our knowledge about the epidemiological and 
multisystem aspects of DM2. It is essential to accurately know the clinical features in order to 
reduce the diagnostic delay in DM2. Furthermore, a better knowledge of its phenotype may 
learn us more about the pathophysiology and eventually lead to a targeted treatment. In our 
effort to accomplish our aim, we sought collaboration with medical specialists from several 
fields of expertise. 
The first part of this thesis covers two studies in a large cohort of patients with FMS. In 
Chapter 2, the results of an epidemiologic study in collaboration with the rheumatologists 
of the Sint Maartenskliniek are described, in which almost 400 patients with suspected FMS 
were genetically tested for DM2. Reasons to perform this study were the striking similarities 
in pain experienced by patients with DM2 and FMS and the suspected underreporting of DM2 
in the Netherlands. 
Serum CK is elevated in many patients with DM2 and other muscular disorders and, 
together with TSH, often recommended, in the standard diagnostic work-up for patients with 
suspected FMS [31,82]. However, it is unclear whether these tests contribute to the diagnostic 
process in patients with suspected FMS. In Chapter 3 the prevalence of an abnormal CK and 
TSH is determined in 373 patients with suspected FMS, with a previously unknown myopathy 
or thyroid disease, in order to evaluate the diagnostic value of this routine testing. 
Part two covers various multisystem aspects of DM2. The results of an explorative study 
in cooperation with anesthesiologists designed to investigate various qualitative and 
quantitative characteristics of pain in patients with DM2 are described and discussed 
in Chapter 4. The ultimate goal was to provide a tailored treatment strategy. Next to the 
completion of four questionnaires, patients with DM2 underwent quantitative sensory testing 
(QST) to establish mechanical and electrical pain thresholds. The results were compared to 
two control groups: a group of patients with FMS and a group of healthy controls.
In Chapter 5, the results are described of our study that explored the presence and 
characteristics of gastrointestinal symptoms in DM2. Two standardized questionnaires about 
gastrointestinal symptoms were completed and the results were compared to both patients 
with DM1 and healthy controls. In addition, radiologically measured colon transit time was 
investigated in patients with DM2 at the gastroenterology department. 
A subset of patients who participated in the study that explored gastrointestinal 
symptoms mentioned that they had difficulty with swallowing. An orofacial examination was 
performed by an experienced speech therapist, next to a fiberoptic endoscopic evaluation of 
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swallowing (FEES) by a otorhinolaryngologist in all patients with DM2 who reported difficulty 
in swallowing. The results are discussed in Chapter 6. 
Together with both neurologists and otolaryngologists of the neuromuscular centre of 
Pitié-Salpêtrière hospital in Paris, we explored the presence of hearing impairment in patients 
with DM2. Next to a structured interview about hearing symptoms, standardized otologic 
examination, pure tone audiometry, speech audiometry, tympanometry, acoustic middle 
ear muscle reflexes, and brainstem auditory evoked potentials were performed. Chapter 7 
covers the results of this international cross-sectional study. 
In the third part of this thesis the results are discussed (Chapter 8) and summarized 
(Chapter 9). The implication of the findings are discussed and compared with the current 
literature. Also, the findings are translated back to clinical practice and finally, perspectives 
on future research are depicted.
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ABSTRACT
Myotonic dystrophy type 2 (DM2) is a rare, autosomal dominant, multisystem disorder 
with proximal muscle weakness, myotonia, pain and early-onset cataract as important 
symptoms. Given the assumed underreporting of DM2 in the Netherlands combined with the 
predominant role of pain in DM2 as well as in ﬁbromyalgia syndrome (FMS), we hypothesized 
there will be an excess prevalence of DM2 in patients with (suspected) FMS. Our objective 
was to determine the prevalence of DM2 in patients with suspected FMS. A prevalence of 2% 
was considered a relevant excess frequency. Between November 2011 and April 2014, 398 
patients with suspected FMS who had been assessed by a rheumatologist participated in this 
cross-sectional study. Ninety-five percent of the study population was female, with a mean 
age of 42 years. The ﬁnal ICD-9 diagnoses were collected, in 96% the diagnosis was FMS. 
Ninety-two percent met the preliminary 2010 American College of Rheumatology diagnostic 
criteria for FMS. A questionnaire including neuromuscular symptoms was completed. Serum 
creatine kinase was determined, and genetic testing for DM2 was conducted in all patients. 
DM2 was established in only one patient (0.25%, 95% CI 0.04–1.4%), thus disapproving our 
hypothesis of a relevant prevalence of 2%. Our results suggest that patients with suspected 
FMS should not routinely be tested for DM2.
Abbreviations: ACR, American college of Rheumatology; CBT, cognitive behavioral therapy; CI, confidence interval; 
CK, creatine kinase; CNBP, cellular nucleic acid binding protein; DM2, myotonic dystrophy type 2; FMS, fibromyalgia 
syndrome; ICD-9, international classification of disease, version 9; MRC, Medical Research Council scale; NEC, not 
elsewhere specified; SD, standard deviation; SS, symptom severity scale; WPI, widespread pain index.
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INTRODUCTION
Myotonic dystrophy type 2 (DM2) is a rare, dominantly inherited multisystem disorder, with 
proximal muscle weakness, myotonia, pain, and early-onset cataract as the core clinical features 
[1,2]. It is caused by an unstable CCTG repeat expansion in the CNBP gene on chromosome 3q21.3 
[3]. Conﬁrming the diagnosis by genetic testing is important for both genetic counselling as well 
as for cardiac monitoring because cardiac arrhythmias are common and may be prevented 
by implantation of a pacemaker [4]. DM2 seems to be underreported in the Netherlands. There 
are only 45 known genetically proven patients with DM2 from 17 different families (16,600,000 
Dutch inhabitants, a prevalence of 1:370,000). This contrasts with an estimated prevalence in 
Germany of 1:20,000 and even 1:1,830 in Finland [5,6]. DM2 is difﬁcult to recognize, not only due 
to the unfamiliarity with the disorder by most clinicians but also because of the heterogeneous 
phenotype and the rather aspeciﬁc onset [2,7]. The average delay between onset of symptoms 
and genetic conﬁrmation of DM2 is 14 years [8]. DM2 shows some remarkable clinical similarities 
to ﬁbromyalgia syndrome (FMS). FMS is a chronic disorder with an estimated prevalence of 
2%, characterized by generalized musculoskeletal pain, and fatigue, and often with various 
associated symptoms [9,10]. Striking similarities between the two conditions are widespread 
ﬂuctuating pain, a high frequency of fatigue and gastrointestinal symptoms [2,10–15]. 4.4% of the 
Dutch patients with DM2 were formerly diagnosed with FMS (unpublished data). In addition, a 
Finnish study reported that 2 out of 63 (3%) FMS patients had underlying DM2 as the explanation 
for their complaints [16]. We therefore hypothesized that there will be an excess frequency of 
DM2 in patients with suspected FMS.
METHODS
Patients
The local ethical committee approved the cross-sectional study design, which was carried 
out according to the Helsinki Declaration. All patients provided informed consent. Between 
November 2011 and April 2014, all patients who were referred with suspected FMS to the 
outpatient Department of Rheumatology of the Sint Maartenskliniek, a regional and also 
tertiary referral centre [17], were invited for this study. Exclusion criteria were age < 18 years 
and an established other diagnosis responsible for the pain. Patients already attending 
cognitive behavioural therapy (CBT) were also excluded, as study participation might have 
interfered with the goals of their treatment.
Diagnostic criteria FMS
A clinical diagnosis was recorded for each patient, according to the ‘International 
Classiﬁcation of Diseases, ninth Revision’ (ICD-9), based on the judgement of the treating 
rheumatologist [18]. According to the preliminary 2010 American College of Rheumatology 
(ACR) diagnostic criteria for FMS, the widespread pain index (WPI) and symptom severity scale 
(SS) were assessed [19]. WPI is the sum of the number of painful body areas in the last week 
(total score 0-19, a higher score indicating more areas of pain). SS is the sum of the severity of 
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4 items: fatigue, waking unrefreshed, presence of cognitive symptoms, and general somatic 
symptoms (total score 0-12, a higher score indicating more severe symptoms). The criteria for 
FMS are met if WPI ≥ 7 and SS ≥ 5 or WPI 3-6 and SS ≥ 9, with a duration of symptoms of at least 
3 months and exclusion of another diagnosis explaining the pain [19]. The physician making 
the referral was recorded for all patients, i.e. a general practitioner or another rheumatologist 
requesting a second opinion.
Measurements
A short questionnaire including questions about neuromuscular symptoms was completed 
(Figure 2.1). In all patients, serum creatine kinase (CK) was determined in U/l, and the 
presence of DM2 was tested by analysing the CNBP gene for expansion of the CCTG repeat 
using standard methods [20]. The primary outcome measurement was the prevalence of DM2 
in patients with suspected FMS.
Figure 2.1 Questionnaire including neuromuscular symptoms
1. Can you climb the stairs without using the railing?
2. Can you stand up from squat position without using your hands?
3. Can you lift 5 kilogram above your head?
4. After exercise, did your urine ever have the colour of cola?
5. Do your parents or brothers or sisters have muscle weakness or muscle pain?  
If yes, how many family members are affected (parents, brothers, sisters)?
6. Has cataract been diagnosed or did you have surgery for cataract?
Statistics
Data analysis was performed using SPSS (version 21.0). In Finland, the prevalence of DM2 in a 
small cohort of patients with FMS was 3% [16]. We considered a prevalence of 2% as a relevant 
excess frequency of DM2 in patients with suspected FMS. We aimed to include 400 patients to 
be able to assess the DM2 prevalence with sufﬁcient precision (with a 95% conﬁdence interval 
(CI) of ±1.4%). If a relevant excess frequency of DM2 was established, a prediction model was 
planned using logistic regression to test the following predictors: age, sex, subjective muscle 
weakness, number of family members with muscle weakness and/or muscle pain, presence 
of cataract and serum CK. Differences between patients referred by general practitioners and 
as second opinions by other rheumatologists were compared with Mann-Whitney test or chi-
square. P < 0.05 was considered statistically signiﬁcant. 
RESULTS
Between November 2011 and April 2014, 398 patients with suspected FMS were included 
(Figure 2.2, ﬂowchart with inclusion). Ninety-five percent were female, with a mean age 
of 42 years (Table 2.1). Based on the ICD-9, FMS was diagnosed in 96% by the treating 
rheumatologist. In 330 patients, the preliminary 2010 ACR diagnostic criteria for FMS had 
been established, 304 patients met that criteria (92%). 281 patients (71%) were referred by the 
general practitioner; the remainder of the study population had been referred for a second 
No relevant excess prevalence of myotonic dystrophy type 2 in patients with suspected ﬁbromyalgia syndrome
35
Ch
ap
te
r 2
opinion by other rheumatologists. There were no differences between patients referred by 
the general practitioner compared to second opinions in WPI (respectively 12.0 vs. 11.7, P = 
0.70), SS (8.9 vs. 8.6, P = 0.31) and percentage that met the preliminary 2010 ACR diagnostic 
criteria for FMS (92.9% vs. 90.5%, P = 0.45).
Figure 2.2 Flowchart with inclusion of patients 
	
 
Suspected	FMS	
(n	=	640)	
Informed	consent	
(n	=	446)	
Participation	
(n	=	398)	
No	participation	
� CBT	 		(n	=	9)	
� No	show	 		(n	=	25)	
� Dead	 		(n	=	2)	
� Unknown	 		(n	=	12)	
No	consent	(n	=	194)	
Abbreviations: FMS, fibromyalgia syndrome; CBT, Cognitive Behavioural Therapy
Table 2.1 Patient characteristics
Characteristic Study population (n = 398)
Female sex, n(%)
Mean age, years (range)
377 (94.7%)
42 (18-75)
Meeting 2010 ACR criteria for FMS, n=330
Yes n(%)
No n(%)
WPI (0-19), mean (SD)
SS (0-12), mean (SD)
304/330 (92.1%)
26/330 (7.9%)
11.9 (±3.8)
8.8 (±2.0)
Second opinions 117 (29.4%)
ICD-9 diagnosis, n(%)
Fibromyalgia syndrome
Osteoarthrosis, generalized or multiple
Arthropathy/arthralgia
Monoarthritis
Polyarthropathy NEC
Ankylosing spondylitis/Bechterev’s syndrome
Spondylosis
Osteoarthrosis   
Bursitis/enthesiopathy/synovitis
Osteoporosis
Hypermobility syndrome/Ehlers-Danlos syndrome
Lumbago
380 (95.5%)
6 (1.5%)
3 (0.8%)
1 (0.3%)
1 (0.3%)
1 (0.3%)
1 (0.3%)
1 (0.3%)
1 (0.3%)
1 (0.3%)
1 (0.3%)
1 (0.3%)
Abbreviations: ACR, American college of Rheumatology; FMS, fibromyalgia syndrome; WPI, Widespread Pain 
Index; SS, Symptom Severity scale; SD, standard deviation; ICD-9, International Classification of Diseases, 
version 9; NEC, not elsewhere classified
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The DM2 mutation was established in only one patient (0.25%, 95% CI 0.04-1.4%), therefore 
refuting our hypothesis of a relevant excess frequency of DM2 in patients with suspected 
FMS. No prediction model could be made to identify speciﬁc factors to predict DM2. The 
patient with DM2 was a 48-year-old woman (Table 2.2). Clinically, she was diagnosed with 
FMS by her treating rheumatologist. However, she did not meet the formal preliminary 
2010 ACR diagnostic criteria for FMS. On neurologic examination by a neurologist, she had 
slight proximal muscle weakness, but no clinical myotonia or elevated CK. Ophthalmologic 
examination revealed no cataract. The results of the questionnaire including neuromuscular 
symptoms are shown in Table 2.3. There were no differences between the answers of this 
patient with DM2 and those of the majority of patients with FMS. More than half of the patients 
with FMS reported family members with similar symptoms, which is in accordance with the 
known familial aggregation of FMS [22].
Table 2.2 Signs and symptoms of patient with DM2
Characteristic Patient with DM2
Sex
Age at diagnosis of DM2
Meeting 2010 ACR criteria for FMS
ICD-9 diagnosis
Serum CK (U/l)
Age of symptom onset
Description of pain
Muscle weakness
Clinical myotonia
Cataract
Other characteristics
Female
48 years
No (WPI 1, SS 6)
FMS
104
12 years
Intermitting, generalized, mainly after exercise, reduced 
by warmth
Slight weakness m. iliopsoas (MRC 4)
Absent
Absent
2 spontaneous abortions
Problematic anesthesia during uterus extirpation
3 adult daughters were later also genetically diagnosed 
with DM2 
Abbreviations: DM2, myotonic dystrophy type 2; ACR, American college of Rheumatology; WPI, Widespread Pain 
Index, SS, Symptom Severity scale. ICD-9, International Classification of Diseases, version 9; FMS, fibromyalgia 
syndrome; CK, creatine kinase (normal value 0-170 U/l), MRC, Medical Research Council scale (0-5) [21].
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Table 2.3 Results of questionnaire including neuromuscular symptoms 
Characteristic DM2
N=1
Suspected FMS
Answer^ n/N (%)^^
DM2 mutation
Climbing stairs without support
Rising from squat
Lifting 5 kg above head
Presence of cola colored urine
Family members* with similar symptoms
If yes, number**, median (range) 
Presence of cataract
+
Yes
Yes
Yes
No
Yes
4
No
-
Yes 
Yes
Yes
No
Yes
1 (1-7)
No 
249/366 (68.0%)
225/364 (61.8%)
181/361 (50.1%)
323/362 (89.2%)
201/363 (55.3%)
350/367 (95.4%)
Abbreviations: DM2, myotonic dystrophy type 2; FMS, fibromyalgia syndrome.
^The answer of the majority of the suspected patients with FMS is shown.
^^ n = number of ‘answer of the majority’, N = number of total responders for each question (there were missing 
values for each question). 
* First degree family members with complaints of muscle weakness or muscle pain.
** Number of family members with similar symptoms
DISCUSSION
In this large cross-sectional study in 398 patients with suspected FMS, only one patient 
was identiﬁed with the DM2 mutation (0.25%), so no relevant excess frequency of DM2 was 
found. The strengths of our study are a large sample size, use of genetic testing as the golden 
standard, and a full rheumatologic evaluation of all patients. However, patient selection 
– given the tertiary function of the Sint Maartenskliniek – might not be representative for 
patients in general with (suspected) FMS. These patients have possibly less severe and/or 
more atypical complaints. Nevertheless, in our study there were no differences between 
patients referred by the general practitioner and patients referred as second opinion by 
other rheumatologists regarding prevalence and severity of FMS. Also, it seems unlikely 
that we underestimated the DM2 prevalence in our study due to selection of FMS patients 
whom might have already undergone testing for DM2 prior to referral, as DM2 is unknown 
among many clinicians, especially rheumatologists, and is not regularly tested. Therefore, 
our estimate of a prevalence of 0.25% can be expected to be accurate. A possible explanation 
for the lack of a relevant excess prevalence of DM2 in FMS is that the prevalence of DM2 in 
the Netherlands in general is much lower than we assumed prior to this study. Therefore, 
although DM2 might still be more frequent among patients with suspected FMS than in the 
general population, there will still be a low prevalence. The occurrence of DM2 in Germany 
and Finland may be much higher due to a founder effect, as several studies suggest that 
DM2 mutations in Europe have a single ancestral founder [5,6,23-25]. A further study is needed 
to establish the general prevalence of DM2 in the Netherlands. The prevalence of 0.25% 
DM2 in patients with suspected FMS is much lower than reported by Auvinen et al. (3%, 
2 patients with DM2 out of 63 FMS patients) [16]. This could be due to the aforementioned 
higher background prevalence in Finland [6]. Alternatively, however, this was probably in part 
an overestimation as these 2 patients with DM2 appeared to be sisters. The relatively small 
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sample size of Auvinen et al. might also have led to a coincidental high prevalence. Although 
the study population in both studies differed to some extent (‘suspected FMS’ in the present 
study versus ‘established FMS’) and could also have caused the difference in prevalence 
found: 92% of our study population met the preliminary 2010 ACR diagnostic criteria for FMS, 
and none of them had DM2. 
The case of DM2 reported in the present study demonstrates once again how difﬁcult 
it can be to establish DM2 as the diagnosis. The slight proximal muscle weakness could have 
led to the suspicion of a neuromuscular disorder. However, there were no other signs or 
symptoms that suggested the diagnosis DM2 in this case (no clinical myotonia, no cataract, 
and a normal CK). The delay between onset of symptoms and conﬁrmation of the diagnosis 
was 36 years. 
In conclusion, we did not ﬁnd a relevant excess prevalence of DM2 in patients with 
suspected FMS. Based on this ﬁnding, we propose that genetic testing for DM2 should not 
routinely be performed in patients with suspected FMS.
No relevant excess prevalence of myotonic dystrophy type 2 in patients with suspected ﬁbromyalgia syndrome
39
Ch
ap
te
r 2
REFERENCES
1. Ricker K, Koch MC, Lehmann-Horn F, et al. Proximal myotonic myopathy: a new dominant disorder 
with myotonia, muscle weakness, and cataracts. Neurology 1994;44:1448-52. 
2. Day JW, Ricker K, Jacobsen JF, et al. Myotonic dystrophy type 2: molecular, diagnostic and clinical 
spectrum. Neurology 2003;60:657-64.
3. Liquori CL, Ricker K, Moseley ML, et al. Myotonic dystrophy type 2 caused by a CCTG expansion in 
intron 1 of ZNF9. Science 2001;293(5531):864-7.
4. Wahbi K, Meune C, Bécane HM, et al. Left ventricular dysfunction and cardiac arrhythmias are 
frequent in type 2 myotonic dystrophy: a case control study. Neuromuscul Disord 2009;19(7):468-72.
5. Ricker K. Myotonic dystrophy and proximal myotonic myopathy. J neurol 1999;246(5):334-8.
6. Suominen T, Bachinski LL, Auvinen S, et al. Population frequency of myotonic dystrophy: higher 
than expected frequency of myotonic dystrophy type 2 (DM2) mutation in Finland. Eur J Hum 
Genet 2011;19(7):776-82.
7. Udd B, Meola G, Krahe R, et al. 140th ENMC International Workshop: Myotonic Dystrophy DM2/
PROMM and other myotonic dystrophies with guidelines on management. Neuromuscul Disord 
2006;16(6):403-13.
8. Hilbert JE, Ashizawa T, Day JW, et al. Diagnostic odyssey of patients with myotonic dystrophy. J 
Neurol 2013;260(10):2497-2504.
9. Wolfe F, Ross K, Anderson J, Russel IJ, Hebert L. The prevalence and characteristics of fibromyalgia 
in the general population. Arthritis Rheum 1995;38(1):19-28.
10. Mease PJ, Clauw DJ, Arnold LM, et al. Fibromyalgia syndrome. J Rheumatol 2005;32(11):2270-7.
11. George A, Schneider-Gold C, Zier S, Reiners K, Sommer C. Musculoskeletal pain in patients with 
myotonic dystrophy type 2. Arch Neurol 2004;61(12):1938-42.
12. Tieleman AA, van Vliet J, Jansen JB, van der Kooi AJ, Borm GF, van Engelen BG. Gastrointestinal 
involvement is frequent in Myotonic Dystrophy type 2. Neuromuscul Disord 2008;18(8):646-9.
13. Tieleman AA, Knoop H, van de Logt AE, Bleijenberg G, van Engelen BG, Overeem S. Poor sleep 
quality and fatigue but no excessive daytime sleepiness in myotonic dystrophy type 2. J Neurol 
Neurosurg Psychiatry 2010;81(9):963-7.
14. Udd B, Meola G, Krahe R, et al. Myotonic dystrophy type 2 (DM2) and related disorders report of the 
180th ENMC workshop including guidelines on diagnostics and management 3-5 December 2010, 
Naarden, The Netherlands. Neuromuscul Disord 2011;21(6):443-50.
15. Björkegren K, Wallander MA, Johansson S, Svärdsukk K. General symptom reporting in female 
fibromyalgia patients and referents: a population-based case-referent study. BMC Public Health 
2009;9:402.
16. Auvinen S, Suominen T, Hannonen P, Bachinski LL, Krahe R, Udd B. Myotonic dystrophy type 2 found 
in two of sixty-three persons diagnosed as having fibromyalgia. Arthritis Rheum 2008;58(11):3627-31.
17. van Koulil S, van Lankveld W, Kraaimaat FW, et al. Tailored cognitive-behavioural therapy and 
exercise training improves the physical fitness of patients with fibromyalgia. Ann Rheum Dis 
2011;70(12):2131-3.
CHAPTER 2
40
18. CDC. ICD-9-CM, International Classification of diseases, 9th revision, Clinical Modification, 3 
Volumes, 1979-2009.
19. Wolfe F, Clauw DJ, Fitzcharles MA, et al. The American College of Rheumatology preliminary 
diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res 
2010;62(5):600-10.
20. Kamsteeg EJ, Kress W, Catalli C, et al. Best practice guidelines and recommendations on the 
molecular diagnosis of myotonic dystrophy types 1 and 2. Eur J Hum Genet 2012;20(12):1203-8.
21. Medical Research Council, Aids to the examination of the peripheral nervous system, Memorandum 
45, Pendragon House, London; 1976.
22. Arnold LM, Hudson JI, Hess EV, Ware AE, Fritz DA, Auchenbach MB, et al. Family study of fibromyalgia. 
Arthritis Rheum 2004;50(3):944-52.
23. Liquori CL, Ikeda Y, Weatherspoon M, et al. Myotonic dystrophy type 2: human founder haplotype 
and evolutionary conservation of the repeat tract. Am J Hum Genet 2003;73(4):849-62.
24. Bachinski LL, Udd B, Meola G, et al. Confirmation of the type 2 myotonic dystrophy (CCTG)n 
expansion mutation in patients with proximal myotonic myopathy/proximal myotonic dystrophy 
of different European origins: a single shared haplotype indicates an ancestral founder effect. Am 
J Hum Genet 2003;73(4):835-48.
25. Coenen MJ, Tieleman AA, Schijvenaars MM, et al. Dutch myotonic dystrophy type 2 patients and 
a North-African DM2 family carry the common European founder haplotype. Eur J Hum Genet 
2011;19(5):567-70.
No relevant excess prevalence of myotonic dystrophy type 2 in patients with suspected ﬁbromyalgia syndrome
41
Ch
ap
te
r 2

1Department of Rheumatology, Sint Maartenskliniek, Nijmegen, the Netherlands
2Department of Neurology, Canisius Wilhelmina Ziekenhuis, Nijmegen, the Netherlands
3Neuromuscular Centre Nijmegen, Department of Neurology, Radboud UMC, The Netherlands
4Radboud Institute for Health Sciences, IQ healthcare, Radboud UMC, Nijmegen, The Netherlands
Rheumatology 2016 Jul;55(7):1273-6
3.
The value of routine creatine kinase and thyroid 
stimulating hormone testing in patients with suspected 
fibromyalgia: a cross-sectional study
Nienke Lesuis1, Judith van Vliet2,3, Nadine Boers1, Nathan den Broeder1, 
Hans A. Cats1, Marlies E. J. L. Hulscher4, Aad Verrips2 
and Alfons A. den Broeder1
CHAPTER 3
44
ABSTRACT
Objective. The aim was to examine the prevalence of abnormal creatine kinase (CK) and 
thyroid stimulating hormone (TSH) values and previously unknown myopathy or thyroid 
disease in patients with suspected fibromyalgia syndrome (FMS). 
Methods. All adult patients with suspected FMS referred to the study hospital between 
November 2011 and April 2014 could participate. Patients with a history of myopathy 
or a previous diagnosis of thyroid disorder were excluded. Outcome measures were the 
percentages of abnormal CK and TSH values and the final diagnosis in those patients.
Results. Three hundred and seventy-three patients were included in this study (94% female, 
mean age 42 years). Of these patients, 7.5% (95% CI: 5.2-10.6%) had an abnormal CK 
according to the local reference values. Applying the European Federation of the Neurological 
Societies guideline, this changed to 0.5% (95% CI: 0.2-1.9%). In none of these patients was 
hyperCKemia-related myopathy diagnosed, and the final diagnosis was FMS in 89% of the 
patients. Of the total number of patients, 3.5% (95% CI: 2.1-5.9%) had an elevated TSH and 
1.4% (95 CI: 0.6-3.1%) a lowered TSH, with one patient having a somewhat lowered free 
thyroid hormone level. The final diagnosis was FMS in all these patients.
Conclusion. Abnormal CK and TSH values are rare in patients with suspected FMS and do 
not result in an alternative diagnosis. Therefore, it seems that routine testing of CK and TSH 
levels in patients with suspected FMS referred to secondary care does not contribute to the 
diagnostic process.
Abbreviations: ACR, American college of Rheumatology; AS, ankylosing spondylitis; CI, confidence interval; CK, 
creatine kinase; FMS, fibromyalgia syndrome; FT4, free thyroid hormone; ICD-9, international classification of dis-
ease, version 9; SD, standard deviation; TSH, thyroid stimulating hormone.
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INTRODUCTION
Fibromyalgia syndrome (FMS) is a chronic pain syndrome mainly affecting women. The 
prevalence is around 2% and because of this high prevalence and its large impact on the 
quality of life of patients, FMS is a major health issue [1,2]. In addition, owing to disputes about 
aetiology, pathogenesis and classification, FMS is still a somewhat controversial disease 
[3,4]. FMS can be diagnosed using the preliminary 2010 American college of Rheumatology 
(ACR) diagnostic criteria. One of those criteria is the absence of another disease that causes 
the complaints [5]. Although not specifically included in these diagnostic criteria, numerous 
blood tests have been recommended as routine screening for patients with suspected FMS to 
exclude alternative diagnoses [6]. However, it is still unclear whether these tests contribute to 
the diagnostic process in patients with suspected FMS. Both creatine kinase (CK) and thyroid 
stimulating hormone (TSH) are frequently mentioned tests in the routine diagnostic work-up 
of FMS owing to the presumed similarities between FMS and myopathies or hypothyroidism 
[4,6-10]. However, the routine use of CK and TSH testing is, to our knowledge, not adequately 
supported by data. For example, there are no clear data to suggest that there is indeed a 
higher pre-test chance of myopathy or thyroid disease in patients with suspected FMS 
compared with the general population. Also, data are absent on the presumed increased 
chance of abnormal CK and TSH values in patients with suspected FMS compared with 
healthy controls. Finally, the added value of CK and TSH testing has not been assessed. Our 
aim was therefore to explore the diagnostic value of CK and TSH testing in patients with 
suspected FMS. More specifically, we aimed to determine the prevalence of abnormal CK 
and TSH values and the prevalence of previously unknown myopathy or thyroid disease in 
patients with suspected FMS.
METHODS
Study design
The present cross-sectional study used data obtained from a study that examined the 
prevalence of myotonic dystrophy type 2 among patients with suspected FMS. Details on 
the methods of the original study are described in Chapter 2 of this thesis [11]. The methods 
relevant to our study will be described below. The local ethical committee approved both the 
original study and this study (CMO Nijmegen Arnhem: 3655109111), and all patients provided 
informed consent. 
Setting and participants
All consecutive patients with suspected FMS referred to the outpatient clinic of the 
rheumatology department at the Sint Maartenskliniek (specialized hospital in rheumatology, 
orthopaedics and rehabilitation medicine; The Netherlands) between November 2011 and 
April 2014 were eligible for participation. Exclusion criteria were age < 18 years, an established 
other diagnosis responsible for the pain and currently receiving cognitive behavioural 
therapy (as participation in the original study might interfere with its goals). In addition, we 
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applied an extra exclusion criterion in the present study: having an established diagnosis of 
myopathy or thyroid disorder. 
Outcome measures and data collection 
Outcome measures were the percentage of patients with abnormal CK and TSH values 
and the final diagnosis in those patients. Baseline patient characteristics were retrieved 
from the patients’ charts (age, sex, medical history, final diagnosis and whether the patient 
was referred to the study centre as a second opinion). The last of these characteristics was 
defined as the patient being seen in the last year by another secondary care specialist for the 
same complaints as presented during the first visit at the study centre. The final diagnosis 
(ICD-9 code) was determined by the treating rheumatologist using a protocolized diagnostic 
approach (history taking, physical examination, a neuromuscular questionnaire and the 
preliminary 2010 ACR diagnostic criteria for FMS). Serum CK and TSH were determined in all 
patients at the clinical laboratory of the study centre. The reference values used in the study 
centre for a normal CK in men and women were < 200 and < 170 U/l,  respectively. As there 
is debate on the reference values for CK, we also used the hyperCKemia values proposed 
by the European Federation of the Neurological Societies [12]. According to this guideline, 
hyperCKemia is present when CK ≥ 504 U/l for non-black men and ≥ 325 U/l for nonblack 
women [12]. CK levels may vary within individuals (e.g. after physical exercise); there-fore, CK 
testing was repeated if the first test result was abnormal. A normal TSH was defined as a TSH 
between 0.4 and 4.0 mU/l. Free thyroid hormone (FT4) was assessed when TSH was abnormal 
(reference values for normal FT4: 8 - 22 pmol/l). In the event of abnormal TSH or FT4 values, 
no repeated testing was performed because TSH and FT4 values show no relevant day-to-
day variation [12]. 
Data analysis
Statistical analysis was performed using STATA version 13.1. All outcome measures are given 
as percentages or means and include the 95% CI or SD, as appropriate. A post hoc sensitivity 
analysis was performed, excluding patients referred as a second opinion.
RESULTS
Setting and participants
All 398 patients included in the original study were considered for participation in the present 
study. We had to exclude 23 patients because of known previous myopathy or thyroid 
disorder (Figure 3.1). As a result of missing data on CK and TSH values in two patients, 373 
patients were included in the final analysis [mean age of 42 (11) years, 94% female]. Of the 
patients with a final ICD-9 diagnosis of FMS, 92% fulfilled the preliminary 2010 ACR diagnostic 
criteria for FMS (Table 3.1).
Results of CK and TSH testing
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The mean CK in our study population was 96 (50) U/l (range: 23-470 U/l) and the mean TSH 
was 1.8 (1.4) mU/l (range: 0.1-17.6 mU/l). Twenty-eight (7.5%; 95% CI: 5.2-10.6%) patients had 
an elevated CK according to the reference standard used at the study centre (range: 171-
470 U/l). Using the European Federation of the Neurological Societies reference standard, 
two (0.5%; 95% CI : 0.2-1.9%) patients had an abnormal CK (357 and 470 U/l, respectively). 
In both of these patients, a repeated CK test was normal. No diagnosis of hyperCKemia-
related myopathy was given in any of the 28 patients with an abnormal CK, and their final 
diagnoses were FMS (n = 25), osteoporosis (n = 1),  arthropathy/arthralgia (n = 1) and AS 
(n = 1). Eighteen patients had an abnormal TSH value, with 13 (3.5%; 95% CI: 2.1-5.9%) 
patients having an elevated TSH and five (1.4%; 95% CI: 0.6-3.1%) a lowered TSH. One patient 
with an elevated TSH had a slightly reduced FT4 (7.7 pmol/l). This was interpreted by the 
treating rheumatologist as subclinical hypothyroidism unrelated to the FMS complaints, and 
no further action was taken. The final diagnosis in all patients with abnormal TSH values was 
FMS. A sensitivity analysis excluding all second opinion patients yielded similar results to the 
original analyses.
Figure 3.1 Study flowchart 
	
Inclusion	in	final	analyses	
(n	=	373) 	
Excluded	
� Previous	diagnoses	of	thyroid	
disorder	(n	=	22)	
� Previous	diagnosis	of	hyperCKemia	
related	myopathy	(n	=	1)	
 Inclusion	in	this	study		
(n	=	375) 	
	
	
	
Missing	data	on	CK	and/or	TSH	value
(n	=	2)
Participation	in	original	
study	
(n	=	398)
Abbreviations: CK, creatine kinase; TSH, thyroid stimulating hormone
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Table 3.1 Characteristics of the patient population
Characteristic Study population (n = 375)
Sex, female, n(%)
Age, mean (SD), years
Second opinion, n(%)
354 (94%)
42 (11)
107 (29%)
Final clinical diagnosis, n(%)
FMS 
Other*
358 (95%)
17 (5%)
Abbreviations: SD, standard deviation; FMS, fibromyalgia syndrome.
*Other diagnosis were as follows: mono-arthritis; polyarthropathy or polyarthritis unspecified; ankylosing 
spondylitis/Bechterev’s syndrome; spondylosis; osteo-arthrosis; bursitis/enthesiopathy/synovitis; osteoporosis; 
arthropathy/arthralgia; hypermobility syndrome or Ehlers-Danlos syndrome and lumbago or neuralgia, neuritis 
or radiculitis, unspecified.
DISCUSSION
This study suggests that relevant abnormal CK and TSH values and a final diagnosis of 
underlying thyroid disease or hyperCKemia-related myopathy are rare in patients with 
suspected FMS. Therefore, it seems that routine testing of CK and TSH in secondary care 
patients with suspected FMS does not contribute positively to the diagnostic process. 
To our knowledge, this is the first study assessing the diagnostic value of two commonly 
used tests in suspected FMS. Some strong points of our study are the prospective design, the 
well-defined patient population and the relatively large sample size. However, this study has 
some limitations. Firstly, we were not able to compare the CK and TSH results against a gold 
standard. For example, muscle biopsies could have been taken to serve as the gold standard 
for myopathies. However, this was not deemed feasible in the context of our study. Instead, 
we used a combination of history taking, physical examination, a neuromuscular checklist 
and the preliminary 2010 ACR diagnostic criteria for FMS in order to create, in our opinion, 
a reasonable surrogate gold standard. Secondly, there was a relatively high proportion 
of second opinion patients in our study, probably higher than in other rheumatology 
departments. However, the sensitivity analyses with exclusion of second opinion patients 
showed similar results. Therefore, this does not seem to hamper the validity of our findings. 
Thirdly, patients may already have had their CK and TSH tested by the general practitioner. 
This could have caused a selection bias leading to underestimation of the prevalence of 
abnormal CK and TSH testing and associated diseases in our study. This is because patients 
who were already diagnosed with thyroid disorder or hyperCKemia-related myopathy would 
probably not have been referred to the rheumatologist for an FMS work-up. Although a valid 
concern, even if the majority of patients had received CK and TSH testing by the general 
practitioner this would not invalidate the generalizability of our results to other secondary 
care rheumatology departments. However, we would encourage the execution  of a similar 
study in primary care.
In spite of widespread use of CK and TSH testing in suspected FMS and recommen- 
dations on this topic in some guidelines, our results do not contradict existing evidence. 
The value of routine CK and TSH testing in patients with suspected fibromyalgia
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Although this may seem counterintuitive, this has to do with the aforementioned lack of data 
on CK and TSH testing in suspected FMS. Publications suggesting that routine CK or TSH testing 
is relevant in the diagnostic work-up of FMS base this recommendation on the presumed 
similarity of symptoms between FMS and thyroid disease or myopathies [4,6,7]. However, these 
recommendations are not based on prevalence data, as provided in our study, and also 
seem to ignore the very low prevalence of clinically relevant myopathies. Furthermore, for 
both CK and TSH, studies on normal values in healthy controls are available. Regarding CK, 
the median value in healthy controls was 84 and 122 U/l for women and men, respectively 
[14]. With regard to TSH, the prevalence of abnormal TSH ranged from 7.3 to 10.4% [15-17]. 
As our results come close to these results in the normal population, they support our 
conclusion of not using routine CK and TSH testing in patients with suspected FMS. Based on 
these studies, routine testing in patients with suspected FMS would be as irrational as routine 
testing in the whole general population. 
Finally, with regard to CK testing there are some additional limitations. Several 
studies claim that CK in general is not a good test because of its low specificity. There is 
a wide variation in serum CK levels in the healthy population, dependent on physiological 
factors such as sex, race and recent physical exercise [14,18]. Therefore, the reference values for 
serum CK are subject to debate [12]. In our study, the use of either strict or liberal reference 
values had a large impact on the number of patients with abnormal values (28 vs 2 patients, 
respectively), with the two highest CK values turning out to be false positives after repeated 
testing. Furthermore, elevated serum CK can reflect a muscular disorder but can also occur 
in other conditions such as hypothyroidism, drug use, alcoholism, muscle trauma, infections 
and malignancies [19-21]. 
In summary, it seems that routine CK and TSH testing did not contribute to the 
diagnostic process in any of the studied patients. Therefore, we recommend against the 
routine use of CK and TSH testing  in patients with suspected FMS seen at a secondary 
care centre. However, elective testing in patients with signs and or symptoms suggestive of 
muscular or thyroid disease should still be done and be followed by appropriate diagnostic 
or therapeutic steps.
CHAPTER 3
50
REFERENCES
1. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromyalgia 
in the general population. Arthritis Rheum 1995;38:19-28. 
2. Hoffman DL, Dukes EM. The health status burden of people with fibromyalgia: a review of studies 
that assessed health status with the SF-36 or the SF-12. Int J Clin Pract 2008;62:115-26.
3. Wolfe F. Fibromyalgia wars. J Rheumatol 2009;36:671-8.
4. Wolfe F, Häuser W. Fibromyalgia diagnosis and diagnostic criteria. Ann Med 2011;43:495-502.
5. Wolfe F, Clauw DJ, Fitzcharles MA, et al. The American College of Rheumatology preliminary 
diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res 
2010;62:600-10.
6. Häuser W, Wolfe F. Diagnosis and diagnostic tests for fibromyalgia (syndrome). Reumatismo 
2012;64:194-205. 
7. Udd B, Meola G, Krahe R, et al. Myotonic dystrophy type 2 (DM2) and related disorders: report of the 
180th ENMC workshop including guidelines on diagnostics and management 3-5 December 2010, 
Naarden, The Netherlands. Neuromuscul Disord 2011;21:443-50.
8. Neeck G, Riedel W. Thyroid function in patients with fibromyalgia syndrome. J Rheumatol 
1992;19:1120-2.
9. Wilson J, Walton JN. Some muscular manifestations of hypothyroidism. J Neurol Neurosurg 
Psychiatry 1959;22:320-4.
10. Hochberg MC, Koppes GM, Edwards CQ, Barnes HV, Arnett FC Jr. Hypothyroidism presenting as a 
polymyositis-like syndrome. Report of two cases. Arthritis Rheum 1976;19:1363-6.
11. van Vliet J, Verrips A, Tieleman AA, et al. No relevant excess prevalence of myotonic dystrophy type 
2 in patients with suspected fibromyalgia syndrome. Neuromuscul Disord 2016;26:370-3.  
12. Kyriakides T, Angelini C, Schaefer J, et al. EFNS guidelines on the diagnostic approach to pauci- or 
asymptomatic hyperCKemia. Eur J Neurol 2010;17:767-73. 
13. Ehrenkranz J, Bach PR, Snow GL, et al. Circadian and circannual rhythms in thyroid hormones: 
determining the TSH and free T4 reference intervals based upon time of day, age, and sex. Thyroid 
2015;25:954-61.
14. Lilleng H, Abeler K, Johnsen SH, et al. Variation of serum creatine kinase (CK) levels and prevalence 
of persistent hyperCKemia in a Norwegian normal population. The Tromsø Study. Neuromuscul 
Disord 2011;21:494-500.
15. Ittermann T, Gläser S, Ewert R, et al. Serum thyroid-stimulating hormone levels are not associated 
with exercise capacity and lung function parameters in two population based studies. BMC Pulm 
Med 2014;14:145.
16. Kvetny J, Ellervik C, Bech P. Is suppressed thyroid stimulating hormone (TSH) associated with 
subclinical depression in the Danish General Suburban Population Study? Nord J Psychiatry 
2015;69:282-6.
17. Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T4, and thyroid antibodies in the United 
States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J 
Clin Endocrinol Metab 2002;87:489-99.
The value of routine CK and TSH testing in patients with suspected fibromyalgia
51
Ch
ap
te
r 3
18. Brewster LM, Mairuhu G, Sturk A, van Montfrans GA. Distribution of creatine kinase in the general 
population: implications for statin therapy. Am Heart J 2007;154:655-61.
19. Reijneveld JC, Notermans NC, Linssen WH, Wokke JH. Benign prognosis in idiopathic hyper-CK-
emia. Muscle Nerve 2000;23:575-9.
20. Simmons Z, Peterlin BL, Boyer PJ, Towfighi J. Muscle biopsy in the evaluation of patients with 
modestly elevated creatine kinase levels. Muscle Nerve 2003;27:242-4.
21. Prelle A, Tancredi L, Sciacco M, et al. Retrospective study of a large population of patients 
with asymptomatic or minimally symptomatic raised serum creatine kinase levels. J Neurol 
2002;249:305-11. 

Part II
Multisystem aspects 
of myotonic dystrophy type 2

1Department of Neurology, Canisius Wilhelmina Hospital, Nijmegen, the Netherlands
2Neuromuscular Centre Nijmegen, Department of Neurology, Radboud UMC, The Netherlands
3Department of Anesthesiology, Pain and Palliative Medicine, Radboud UMC, Nijmegen, the Netherlands
4Center for Sensory-Motor Interaction, Department of Health Sciences and Technology, Aalborg University, Denmark
J pain 2018;19(8):920-30
4.
Qualitative and quantitative aspects of pain in patients 
with myotonic dystrophy type 2
Judith van Vliet1,2, Alide A. Tieleman2, Aad Verrips1, Hans Timmerman3, 
Robert T.M. van Dongen1,3, Baziel G.M. van Engelen2 
and Oliver H.G. Wilder-Smith3,4
CHAPTER 4
56
ABSTRACT
Pain is a common but often ignored symptom in patients with myotonic dystrophy type 2 
(DM2). In this explorative study, we assessed qualitative and quantitative aspects of pain 
in DM2 using four questionnaires and quantitative sensory testing. Both a disease control 
group (fibromyalgia (FMS)) and healthy controls were used to compare the results, as pain 
in DM2 shows many clinical similarities to pain in FMS. Thirty-four patients with genetically 
confirmed DM2 (71% female, mean age 54 years), 28 patients with FMS and 33 healthy controls 
were included, both age- and sex-matched. Pain prevalence was 65% in DM2, 100% in FMS (P 
< 0.001) and 15% in healthy controls (P < 0.001). A correlation was found between pain and 
several aspects of quality of life. The mean of the pressure pain thresholds was lower in DM2 
than in healthy controls (P = 0.016), with the largest differences in the rectus femoris, trapezius 
and thenar muscles. Mechanical and electric pain thresholds were significantly higher in DM2 
than in FMS, no differences were found in electric pain thresholds between DM2 and healthy 
controls. These results confirm that pain is a frequent and important symptom in patients 
with DM2. Peripheral mechanisms of pain seem to play a role in DM2. The widespreadness 
of the hyperalgesia suggests central sensitization, but this finding was not supported by 
the other results. This study opens new avenues for further research and eventually novel 
treatment strategies, both in DM2 as well as other muscular disorders.
Abbreviations: ACR, American College of Rheumatology; BMI, body mass index; CNS, central nervous system; CPM, 
conditioned pain modulation; DM2, myotonic dystrophy type 2; EPT, electric pain detection threshold; EPTT, electric 
pain tolerance threshold; EST, electric sensation threshold; FMS, fibromyalgia syndrome; HADS, hospital anxiety and 
depression scale; HC, healthy controls; LGMD, limb girdle muscular dystrophy; MPQ-DLV, McGill pain questionnaire, 
Dutch language version; mRS, modified Rankin Scale; NA, not applicable; NRS, numeric rating scale; NWC, number 
of words chosen; PCS-DV, pain catastrophizing scale, Dutch Version; PPT, pressure pain threshold; PRI-R, pain rating 
index, based on rank values; QST, quantitative sensory testing; SD, standard deviation; SF-36, 36 item short form 
health survey; SS, symptom severity scale; VAS, visual analogue scale; WPI, widespread pain index.
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INTRODUCTION 
Myotonic dystrophy type 2 (DM2) is a dominantly inherited, multisystem disorder caused by 
an unstable CCTG repeat expansion in the CNBP gene on chromosome 3q21.3 [1]. The mean 
age of onset is 34 years and the phenotype is rather heterogeneous [2,3]. Core symptoms are 
progressive muscle weakness, myotonia, pain and early-onset cataract. Other characteristics 
are sleep disturbances, fatigue, gastrointestinal symptoms and involvement of the heart, 
endocrine and central nervous systems [2, 4-6].
Pain is a common as well as a highly relevant problem for many patients with DM2, with 
an estimated lifetime prevalence of 76% and a negative impact on quality of life [7-10]. There 
have been a few single cases in which treatment using NSAIDs, carbamazepine, phenytoin, 
a short-term course of corticosteroid therapy, baclofen, tizanidine and gabapentin had 
a positive effect on pain [11-14]. The pathophysiology of pain in DM2 is, however, poorly 
understood and has not yet been fully studied; tailored treatment strategies are largely 
unknown [15].
In general, peripheral as well as central sensitization are likely to play a prominent role 
in chronic musculoskeletal pain [16]. Muscle pain and hyperalgesia are initiated by the release 
of endogenous substances in the muscle during trauma or inflammatory injury, eventually 
causing peripheral sensitization [17]. In turn, peripheral sensitization may induce central 
sensitization [17,18]. Central sensitization is the amplification of neural signalling within the 
central nervous system, expressed as spreading or generalized hyperalgesia [19]. Moshourab 
et al. recently reported that both peripheral mechanisms as well as central sensitization 
probably play a role in pain in patients with DM2 [20]. To our knowledge, the role of peripheral 
and central sensitization has never been explored in any other muscular disorder. However, 
exploring the mechanisms of pain processing gives direction to a tailored treatment strategy. 
Central sensitization is an established feature of fibromyalgia syndrome (FMS), a 
common chronic pain syndrome [21,22]. The pain experienced by patients with DM2 shows 
important similarities to that of the chronic musculoskeletal pain experienced in FMS, 
including widespread fluctuating pain [23,24]. There are also corresponding additional 
symptoms, including a high frequency of fatigue and gastrointestinal symptoms. Given the 
clinical similarities, we hypothesized that altered central pain processing plays a role in DM2 
as well. In the last decades quantitative sensory testing (QST) has emerged as a technique 
to quantify pain processing by rating the experienced intensity of defined stimuli under 
standardized conditions [13,25,26].
The aim of the present study was to assess prevalence, severity and characteristics of 
pain in patients with DM2, in addition to the quantification of pain processing. The results 
were compared to a disease control group (patients with FMS) and to a healthy control (HC) 
group, both matched for age and sex.
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PATIENTS AND METHODS
Patients
All known genetically confirmed patients with DM2 in the Netherlands were invited to 
participate in this explorative study. The six-point modified Rankin Scale (mRS) was used to 
indicate the degree of disability of patients with DM2 [27]. The age of disease onset, the first 
symptom and the current most severe symptom were documented. 
Two age- and sex-matched control groups were recruited, consisting of patients with 
FMS and healthy controls, respectively. FMS was chosen as disease control group based 
on clinical similarities of pain experienced by patients with DM2 and FMS. All patients 
with FMS were required to meet the preliminary 2010 American College of Rheumatology 
(ACR) diagnostic criteria for FMS [28]. The widespread pain index (WPI, the number of painful 
body areas last week with a range of 0-19) and symptom severity scale (SS, the sum of 
the severity of fatigue, waking unrefreshed, presence of cognitive symptoms and general 
somatic symptoms, range 0-12) were recorded based on these criteria. Healthy controls were 
population-based, meaning that they did not have to be pain free as such.  
Exclusion criteria were: age under 18 years, severe illness in addition to DM2 or FMS 
including a current major depression, active malignant disorder and a known moderate 
to severe neuropathy, recent (< 6 weeks) major surgery and the inability to understand the 
Dutch language. Medical history and current medication were noted. This cross-sectional 
study (NTR4864) was approved by the local ethics committee (NL43167.091.13) and each 
person provided written informed consent before participation.
QUESTIONNAIRES
Pain
The McGill Pain Questionnaire (MPQ-DLV, validated in Dutch) was used to assess various 
aspects of pain [29,30]. It is a well validated and widely used questionnaire [29]. Pain experience 
was specified using 20 groups of pain descriptors (three subclasses: sensory, affective and 
evaluative subgroups, total 63 words); one word (‘the most appropriate’) could be chosen for 
each group. The number of words chosen (NWC, range 0-20) and the pain rating index based 
on the rank values (PRI-R, range 0-63) were documented in total and for the three subclasses. 
Pain intensity was measured using a Visual Analogue Scale (VAS, range 0-100 mm) for present 
pain, maximum pain and minimum pain. The presence of pain was defined as a ‘VAS for 
present pain’ ≥ 10 mm and relevant pain as a ‘VAS for present pain’ ≥ 25 mm. These cut-off 
points were based on a review by Sokka et al., in which a pain intensity of less than 10 mm 
was interpreted as no pain and in which a pain level of less than 25 mm was considered to be 
acceptable by the vast majority of patients with inflammatory or degenerative disorders [31]. 
Pain location was evaluated by marking the painful areas on a diagram representing the front 
and back of a human body divided into 32 body areas.
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Pain catastrophizing
The Pain Catastrophizing Scale (PCS-DV, validated in Dutch) was used to evaluate 
catastrophizing thoughts by reflecting on past painful experiences [32,33]. Participants had 
to indicate the degree to which they experienced each of 13 thoughts or feelings when 
experiencing pain (total range 0-52, a higher score indicating more catastrophizing thoughts). 
Anxiety and depression
The presence of anxiety and depression was identified by the Dutch adaptation of the 
hospital anxiety and depression scale (HADS) [34,35]. It is composed of two 7-item scales, one 
for anxiety and one for depression, both with a score range of 0-21 (a higher score indicating 
more anxiety or depression). Subscale scores above 7 were considered to indicate clinically 
significant symptoms of anxiety or depression [36]. 
Health status
The Dutch version of the SF-36 health survey was used to assess health status [37,38]. The SF-36 
is one of the most widely used surveys to measure health status and comprises four physical 
health scales (physical functioning, physical role functioning, bodily pain and general 
health perception) and four mental health scales (vitality, social functioning, emotional role 
functioning and mental health). All raw scale scores were linearly converted to a 0-100 scale, 
with higher scores indicating a higher level of functioning or well-being.
QUANTITATIVE SENSORY TESTING
QST quantitatively measures pain and central pain processing by applying defined stimuli 
and rating the intensity experienced under standardized conditions [26,39]. QST was conducted 
by two trained examiners with a standard temporal test sequence according to the Nijmegen-
Aalborg Screening QST (NASQ) paradigm [26,39]. Instructions were standardized and read to the 
subjects from an instruction sheet. The use of analgesics was continued during the test. 
Mechanical QST
Pressure pain thresholds (PPT) were obtained in Newton using a pressure algometer with a 
1.0 cm2 probe (Wagner FDX 50). According to the NASQ protocol, the algometer was applied 
bilaterally on the thenar eminence, trapezius (pars transversa), rectus femoris and abductor 
hallucis and in addition on the deltoid and paravertebral muscles at level L4/L5 [26,39]. Subjects 
were instructed to indicate when the pressure became painful. The mean of the 12 PPTs was 
calculated, as well as the mean of each of the six different anatomic sites (right and left).
Electrical QST
Electrical pain thresholds were determined by applying transcutaneous constant current 
electric stimulation (tetanic stimulation at 100 Hz, 0.2ms square waves, self-adhesive 
electrodes 3 cm apart) bilaterally at the rectus femoris and trapezius. The subjects were 
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instructed to indicate when an electric current was felt (EST: electric sensation threshold), 
when the electric stimulation became painful (EPT: electric pain detection threshold) and 
when the pain became intolerable (EPTT: electric pain tolerance threshold). The average of 
three runs for each threshold was measured for each body area. The mean of the 4 different 
areas was calculated for each threshold.
Conditioned pain modulation (CPM)
CPM is calculated to test the ability of the patient to generate descending inhibitory modulation. 
PPT and EPTT (test stimuli), obtained from the rectus femoris on the non-dominant side, 
were determined before and immediately after a cold pressor task (conditioning stimulus) 
[39]. The cold pressor task was used as noxious stimulus. The dominant hand was immersed 
in a bucket filled with ice cubes and water (normally generating a water temperature of 
about 4°C). Patients had to hold their hand in the ice water bucket as long as possible, until 
the sensation became unbearable, with a maximum of three minutes. The duration of the 
immersion was recorded, as well as the intensity of pain every 10 seconds on a Numeric 
Rating Scale (NRS) and the pain at the moment of withdrawal. CPM effect was determined as 
the relative change in percentages in the PPT and EPPT before and immediately after the cold 
pressor task. A positive CPM value was considered as an intact ability to generate descending 
inhibitory modulation.
Statistics
Data were entered in Castor (Ciwit B.V., Amsterdam, the Netherlands), an online data 
management system that meets good clinical practice guidelines. SPSS version 21 was used 
for statistical analysis. Normality of variables was evaluated using the Shapiro-Wilk test. 
Differences between the three groups were compared with analysis of variance (ANOVA, if 
normally distributed) or Kruskal-Wallis (if not normally distributed). If a statistically significant 
difference was found between the three groups, then a post-hoc analysis or Mann-Whitney 
U test was used to compare the results between two groups (DM2 versus FMS; DM2 versus 
healthy controls). Nominal data were compared using chi-square test (or Fisher’s Exact test, if 
appropriate). QST results were compared between subjects with pain and without pain with 
a Mann-Whitney U test, to avoid the influence of pain as a confounder. Also, these results 
were compared in a subgroup analysis of patients with DM2 with pain, patients with FMS with 
pain and healthy controls without pain (Kruskall Wallis). 
For correlation, Spearman’s rho was calculated. One-way ANCOVA was used to assess 
the influence of covariates (NRS, depression score and anxiety score) on the differences 
in the pressure pain thresholds between the three study groups. Nonlinear variables were 
converted in an ordinal scale in this model. P < 0.05 was considered statistically significant. 
Considering the observational study design, we did not correct for multiple testing. Missing 
data are assigned in the tables. In case of missing data in the PCS and SF-36, the mean of the 
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remaining answers was used if less than half of the answers were missing, otherwise they 
were assigned as missing.
RESULTS
Patients
Thirty-four patients with DM2 from 20 different families completed the questionnaires, as did 
28 patients with FMS and 33 healthy controls (Figure 4.1). The three study groups matched 
well for age and sex (Table 4.1). Median mRS in the patients with DM2 was 2 (slight disability; 
unable to perform all previous activities but able to look after one’s own affairs without 
assistance), range was 0-3. Diabetes mellitus type 2 was present in 3 patients with DM2 (9%). 
Pain was reported as the first symptom in 15% of patients with DM2 and as the most disabling 
symptom in 30%. For patients with FMS, mean WPI was 11.5 (SD 3.3), mean SS was 8.3 (SD 1.8).
Figure 4.1 Flowchart with inclusion 
	
	
 
n=34	 n=28	 n=33	
n=28	
No	participation	(16)#	
Excluded		(4)	
-	3	polyneuropathy	
-	1	no	Dutch-language	
 
n=28	 n=31	
Question-
naires	
	QST	
No	match	(27)	
No	participation	(4)	
Excluded	(6)	
-5	severe	illness	
-1	recent	surgery	
No	match	(60)	
No	participation	(3)	
Excluded	(2)	
-1	polyneuropathy	
-1	LGMD*	
 
Assessed	
for	
eligibility	
DM2	
n=54	
FMS	
n=93	
HC	
n=70	
Transport	problem	(3)	
Too	stressful	(1)	
Stroke	(1)	
No	show	(1)	
 
No	show	(2)	
 
Abbreviations: DM2, myotonic dystrophy type 2; FMS, fibromyalgia syndrome; HC, healthy controls; LGMD, limb 
girdle muscular dystrophy; QST, quantitative sensory testing
#Reasons for non-participation in DM2 cohort: too stressful (10), unknown (3), difficulty accepting diagnosis (2), 
transport problem (1)
*One FMS patient was excluded afterwards because of an alternative diagnosis, namely LGMD instead of FMS.
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Table 4.1 Patient characteristics and presence of pain in DM2, FMS and healthy controls
Characteristic DM2
n=34
FMS
n=28
HC
n=33
P-value
3 groupsa DM2-FMSb DM2-FMSb
Female sex, n (%) 24 (71) 22 (79) 21 (64) 0.444
Age (yrs)
mean (SD) range
54 (11)
31-72
50 (11)
27-72
53 (12)
31-69 0.277
Age disease onset (yrs)
mean (SD) range
32 (12)
8-59
31 (13)
13-52
NA
Pain, VAS ≥ 10mm, n (%) 22 (65) 28 (100) 5 (15)^ < 0.001 < 0.001 < 0.001
Pain, VAS ≥ 25mm, n (%) 19 (56) 27 (96) 1 (3) < 0.001 < 0.001 < 0.001
Use of Analgesics, n (%)
Acetaminophen
Codein
NSAID
Tramadol
Opiods
Central acting analgesics*
Other¶
15 (44)
9 (27)
0
4 (12)
1 (3)
2 (6)
5 (18)
2 (6)
25 (89)
21 (75)
7 (25)
12 (43)
5 (18)
6 (21)
6 (21)
1 (4)
3 (9)^^
3 (9)
1 (3)
0
0
0
0
0
< 0.001 < 0.001 0.001
Abbreviations: DM2, myotonic dystrophy type 2; FMS, fibromyalgia syndrome; HC, healthy controls; SD, standard 
deviation; VAS, visual analogue scale; NSAID, non-steroidal anti-inflammatory drug; NA, not applicable.
a P-value according to chi-square or ANOVA 
b P-value according to chi-square or post-hoc analysis (least significant difference t-test).
*DM2: 2 patients used pregabalin, 2 tricyclic antidepressants and 1 baclofen; FMS: 3 patients used pregabalin, 2 
tricyclic antidepressants and 1 gabapentin
¶1 patient with DM2 and 1 patient with FMS used benzodiazepines, 1 patient with DM2 used cannabis
^ Respectively 1. Lumbago and pain in neck and shoulders; 2. Pain ankle, 3. Pain knee, 4. Pain in hip, 5. Arthrosis 
hands and knees.
^^ One patient sporadically uses acetaminophen for pain in the thenar, one sporadically for migraine and one 
occasionally acetaminophen/codein for lumbago.
QUESTIONNAIRES
Pain was present in 65% of patients with DM2, 100% of patients with FMS and in 15% of 
healthy controls (P < 0.001, Table 4.1). Table 4.2 shows the results of the questionnaires. 
No correlation was found between pain intensity (according to ‘VAS present’) and age 
(Spearman’s r = 0.097, P = 0.609) in patients with DM2. A significant correlation was found 
between pain intensity (according to ‘VAS present’) and the items physical role functioning, 
social role functioning and bodily pain in the DM2 cohort (Spearman’s rho -0.405, P = 0.032; 
rho -0.372, P = 0.043 and rho -0.70, P = 0.000, respectively). 
The location of pain is shown in Figure 4.2. Median (P25 - P75) number of painful body 
areas in subjects with pain was 8 (4 - 16) in patients with DM2, 17 (16 - 24) in patients with FMS 
and 1 (1 - 4) in healthy controls (P < 0.001, Kruskall Wallis).
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Figure 4.2 Location of pain in patients with DM2, FMS and healthy controls 
QUANTITATIVE SENSORY TESTING 
QST was performed in 28 patients with DM2, 28 patients with FMS and 31 healthy controls 
(Table 4.3). The mean of the PPT was significantly lower in patients with DM2 than in 
healthy controls (P = 0.016), and significantly higher in DM2 than in FMS (P = 0.009). PPT 
was significantly lower in patients with DM2 than in healthy controls in the rectus femoris, 
thenar and trapezius, while PPT was higher in DM2 than in FMS in the trapezius, paravertebral 
muscles, abductor hallucis and thenar (Figure 4.3). The electric pain thresholds (EST, EPT, 
EPTT) were not significantly different in patients with DM2 compared to healthy controls; they 
were all significantly higher in patients with DM2 than in patients with FMS (P < 0.001). No 
differences were found between the mean of PPT in patients with DM2 with pain (median 
42.1 (30.9 - 59.6)) and without pain (median 44.5 (37.1 - 60.1) P = 0.60). The mean of PPT, EST, 
EPT, EPTT and CPM for PPT and EPTT showed no significant differences between healthy 
controls with (n = 5) and those without (n = 26) pain (P = 0.856, P = 0.815, P = 0.159, P = 0.856, 
P = 0.658, P = 0.775, respectively). A subgroup analysis of patients with DM2 with pain, FMS 
patients with pain and healthy controls without pain is shown in Table 4.4. Mean of PPT is 
significantly lower in DM2 with pain when compared to healthy controls without pain.
The significant difference in PPT between the three study groups still exists after 
adjustment for the covariates NRS (at time of QST measurement), depression score and 
anxiety score (beta before adjustment 0.252; beta after adjustment 0.064; P < 0.001 before 
adjustment; P = 0.017 after adjustment). Depression score was changed in an ordinal scale, 
because this variable was not linear to PPT. 
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Figure 4.3 Pressure pain thresholds in the different anatomic sites 
 
 
 
 
Abbreviations: DM2, myotonic dystrophy type 2; FMS, fibromyalgia syndrome; HC, healthy controls;  PPT, 
pressure pain threshold; N, Newton.
The mean of the right and left site is calculated for each subject for the six different anatomic sites, the median 
of the three study groups is shown. The P-value is shown for DM2 compared to respectively FMS and healthy 
controls. 
○ = outlier
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DISCUSSION
We present a comprehensive study of qualitative as well as quantitative aspects of pain in 
patients with DM2, compared to both a disease- and a healthy control group, with the ultimate 
goal to provide a rational treatment strategy for pain in patients with DM2. We were able to 
confirm previous results regarding the frequency, severity and relevance of pain with respect 
to quality of life in patients with DM2 [8-10,40]. The main finding is mechanical hyperalgesia in 
patients with DM2 compared to healthy controls, mainly present in the rectus femoris, trapezius 
and thenar, suggestive of at least a peripheral mechanism of pain. The presence of central 
sensitization remains unclear based on the results, the higher mechanical and electrical pain 
thresholds in DM2 than in FMS suggest that it is at least less pronounced than in FMS. 
The prevalence of pain (65%) in patients with DM2 in the present study was higher than 
reported by Moxley et al. (46%, p = 0.031), and lower than reported by Peric et al. (86%, p = 0.015) 
[8,40]. The lifetime prevalence of pain was 76% in a study by Suokas et al., Day et al. reported that 
56% of patients with DM2 had a history of muscle pain [2,9]. Pain was most frequently localised 
in the proximal limbs in patients with DM2. Weakness, as previously described in literature, 
is most pronounced in the proximal muscles, suggesting that the most affected muscles are 
also the most painful ones [2,41]. The correlation of pain intensity with several aspects of health-
related quality of life confirms the relevance of pain for patients with DM2. Similar results have 
also been reported in DM2 and in other pain-related diseases [8,10,42,43].
Pressure pain thresholds have been measured before in DM2 in two studies, electrical 
thresholds have never been measured. The finding of lower pressure pain thresholds in 
patients with DM2 in the present study is in accordance with the findings of Moshourab et al., 
who also reported decreased PPT in 23 patients with DM2 with pain compared to healthy 
controls [20]. George et al. only reported a tendency towards local mechanical hyperalgesia 
in a small study of 13 patients with DM2, but no significant differences in PPT between DM2 
and healthy controls [7]. Moshourab et al. reported lower PPT in patients with DM2 with pain 
compared to patients with DM2 without pain [20]. In our study however, no difference was 
found between patients with DM2 with and without pain. 
The decreased pressure pain thresholds may be indicative of a peripheral mechanism 
of pain in DM2, especially since the lowest thresholds were found in the rectus femoris, also 
the site where pain is mostly reported. The widespreadness of the lowered PPT, generalized 
hyperalgesia, may also be a sign of central sensitization [18]. It is known that peripheral 
sensitization may trigger central sensitization. Moshourab et al. reported a slightly elevated 
wind-up in myalgic patients with DM2, another sign of central sensitization [20]. However, the 
absence of differences in electric thresholds in patients with DM2 and healthy controls in the 
present study argue against central sensitization. Both mechanical and electric thresholds 
were higher in the DM2 group than in the FMS group, suggesting that central sensitization plays 
at least a less prominent role in DM2 than in FMS. The confirmation of central sensitization in 
FMS is in accordance with the literature [21,22]. 
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Conditioned pain modulation (CPM) was measured to test inhibitory modulation. 
Inefficient CPM is a well-known feature of FMS [21]. Surprisingly, we did not find significant 
differences in CPM between the three study groups. In general, there is no agreement on 
how to perform CPM, the test stimulus is given during or immediately after the conditioning 
stimulus. The test stimulus in the present study was given after the conditioning stimulus, as is 
recommended by Yarnitski et al. [44]. It is possible that this method partly accounts for the lack 
of differences in CPM. The immersion time in the ice cold water differed significantly between 
the three study groups, this may also have influenced the results. Perhaps CPM was more 
inefficient in our control group than would be expected. There was however no difference in 
CPM between healthy controls with and without pain. Catastrophizing thoughts are known 
to influence CPM, although we did not find a difference in catastrophizing thoughts between 
patients with DM2 and patients with FMS and healthy controls, respectively [43].
The current study protocol to explore pain mechanisms has never been used before 
in patients with DM2 or other muscular disorders. It opens new avenues for novel treatment 
strategies and is the first step in determining a mechanism based treatment. Further research, 
by extending the study protocol to also include measurement of thermal detection and pain 
thresholds, dynamic mechanical allodynia and repetitive pinprick stimuli for pain summation 
may teach us more about the role of central sensitization [25]. Subsequently, functional brain 
imaging could be performed [45]. 
Strengths of our study are an adequate external validity - all known Dutch patients with 
DM2 were invited - and well-matched control groups. Healthy controls were population-based 
and did not necessarily have to be totally pain free. This may have influenced the results, 
however, there was no difference in the QST results between healthy controls with pain 
and those without pain. The uninterrupted use of analgesics during QST may have affected 
the results, as pregabalin, gabapentin and tricyclic antidepressants may decrease central 
sensitization, while on the other hand opioids may induce opioid-induced hyperalgesia [46-48]. 
Non-respondent bias may also have affected our results. Most patients with DM2 who did not 
participate found the study to be ‘too stressful’, suggesting relatively severe disease activity 
and perhaps a higher frequency or more severe pain than in the sample studied. The study 
was limited by the cross-sectional design. The onset of pain in DM2, either localised or in a 
more generalized fashion, remains unknown. This would be of interest for the interpretation 
of the QST results. This is however difficult to determine in a longitudinal study, as the average 
time between onset of symptoms and diagnosing DM2 is 14 years [3].
Furthermore, we did not correct for multiple testing while we performed several 
statistical analyses, so the results must be interpreted with some caution. Using Bonferroni 
as adjustment for multiple testing, the significance level would be set at 0.0008 (59 tests 
were performed). Pain prevalence, VAS scores and six quality of life parameters would still 
be significantly different between DM2 and healthy controls, although the latter two would 
not be different between DM2 and FMS. PPT would still be significantly different for the three 
study groups, but not when DM2 is compared to FMS and healthy controls separately. EST 
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and EPT would remain different between DM2 and FMS. The frequency and severity of pain 
and correlation between pain and quality of life in patients with DM2 still remains when 
Bonferroni is used. However, widespread hyperalgesia would not be demonstrated with this 
stringent method of correction for multiple testing.
In conclusion, this study confirms that pain is an important and frequent symptom in 
patients with DM2 and we established its relevance with respect to quality of life. Mechanical 
hyperalgesia was found in patients with DM2, indicative of the presence of peripheral 
sensitization. The widespreadness of the hyperalgesia suggests central sensitization, but this 
finding was not supported by the other results and needs confirmation with further research. 
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ABSTRACT
The phenotype of myotonic dystrophy type 2 (DM2) shows similarities as well as differences 
to that of myotonic dystrophy type 1 (DM1). Gastrointestinal dysfunction is common in 
DM1 and 25% of the patients consider this to be the most disabling consequence of the 
disease. Little is known about gastrointestinal involvement in DM2. The aim of the study 
was to explore the occurrence and characteristics of gastrointestinal symptoms in patients 
with DM2. This was compared to symptoms in adult-onset patients with DM1, and to age 
and sex-matched healthy controls. Twenty-nine genetically proven patients with DM2 filled 
out two standardized questionnaires about gastrointestinal symptoms; most important 
outcome measures were answers to questions about dysphagia, abdominal pain, and 
constipation. The results were compared to those of 29 adult-onset patients with DM1, and 
to 87 age- and sex-matched healthy controls. Radiological measurement of colon transit 
time was investigated in 18 patients with DM2. Dysphagia for liquids (38%) and solid food 
(41%), abdominal pain (62%), and constipation (62%) were all significantly more common 
among patients with DM2 than among healthy controls, and comparable to their occurrence 
in DM1. Colon transit time was increased in 24% of the patients with DM2. Our results show 
that gastrointestinal symptoms are highly prevalent in patients with DM2. Gastrointestinal 
dysfunction may be attributed to any part of the gastrointestinal tract. The results provide 
new insight into the clinical picture of DM2.
Abbreviations: CI, confidence interval; CNBP, cellular nucleic acid binding protein; CTT, colon transit time; DM1, 
myotonic dystrophy type 1; DM2, myotonic dystrophy type 2; ENMC, European Neuromuscular Centre; PROMM, 
proximal myotonic myopathy; RR, relative risk; SD, standard deviation; ZNF9, zinc finger protein 9.
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INTRODUCTION
Myotonic dystrophy type 2 (DM2, MIM 602668) is a dominantly inherited multisystem disorder 
characterized by progressive proximal muscle weakness, myotonia, early-onset cataract, 
cardiac arrhythmia, and muscle pain [2,3]. The disease was first described by Ricker et al. in 
1994, who coined the term proximal myotonic myopathy (PROMM) [4]. In 2001, the mutation 
responsible for DM2 was identified as a CCTG expansion located in the intron 1 of the zinc 
finger protein 9 (ZNF9) gene on chromosome 3q21.3, currently known as the CNBP gene [5]. 
The clinical picture of DM2 shows similarities as well as differences to that of myotonic 
dystrophy type 1 (DM1) [3]. Shared core features are autosomal dominant inheritance, 
muscle weakness, myotonia, early-onset cataract, and multiorgan involvement with cardiac 
conduction defects, insulin resistance, hypothyroidism and gonadal atrophy. Notably absent 
is a congenital form of DM2, and evidence of anticipation is less striking than in DM1, while 
muscle pain is more prominent in DM2 [6]. 
Gastrointestinal dysfunction, a predominant feature in DM1 [1], has not yet been 
examined in DM2. However, dysphagia, vomiting due to pyloric stenosis, and constipation 
were described in PROMM and DM2 case reports [4,7-10]. Dysphagia and constipation were 
already mentioned in the first European Neuromuscular Centre (ENMC) International 
Workshop Report about PROMM as supportive findings to establish the diagnosis [11], but 
so far the expert opinion has not been corroborated by clinical research. We performed a 
prospective nationwide study to explore the presence and characteristics of gastrointestinal 
dysfunction in genetically proven patients with DM2 and compared them to adult-onset 
patients with DM1 and healthy controls.
PATIENTS AND METHODS
Patients
In the Netherlands, 32 patients from 12 families are known with genetically proven DM2. 
All were   retrieved from CRAMP, the Dutch neuromuscular database and approached for 
participation with the consent of their treating physician, according to the Helsinki criteria [12]. 
Two age- and sex-matched control groups were selected, one from known adult-onset patients 
with DM1, the other from healthy spouses of patients visiting our outpatient department. The 
local ethics committee approved the study. All patients and controls gave written informed 
consent. The exclusion criteria for participating were untreated hypothyroidism or other co 
morbidity with influence on the gastrointestinal tract. 
Methods
Participants were asked to fill out two questionnaires about gastrointestinal symptoms. The 
first questionnaire, the Dutch Gastrointestinal Symptoms Questionnaire, covers symptoms 
from all parts of the gastrointestinal tract [13]. It contains questions about the severity of 
gastrointestinal symptoms during the last 4 weeks. Symptoms are rated from 0 to 6, 0 meaning 
‘no complaints’ and 6  representing ‘the worst imaginable severity of that symptom’. Answers 
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to questions about dysphagia, abdominal pain, and constipation were considered the most 
important outcome measures, since those symptoms are known to be highly prevalent in 
DM1, relevant in clinical practice, and probably all the result of impaired motility. A cut-off 
between 0 and 1 was used to estimate the frequencies of these symptoms.
The second questionnaire contains questions about defecation frequency (rated 
1–6), feeling of incomplete evacuation (rated 1–4), difficult evacuation (rated 1–4), and 
pain during defecation straining (rated 1–4). Answers to these four questions were used to 
calculate the constipation score, which has a reliability (Cronbach’s a) of 0.82. The mean 
constipation score for healthy controls is 6, while the mean constipation score for patients 
with defecation complaints visiting a surgeon is 8 [14]. All patients with DM2 were also asked 
to undergo radiological measurement of colon transit time. The procedure was performed as 
described earlier [15]. In short, ten radiopaque markers were ingested daily for 10 consecutive 
days. On the eleventh day an abdominal X-ray was performed. The markers were counted in 
total. According to a validated formula the total colon transit time in hours was calculated 
by multiplying the number of markers by 2.4 [16]. Increased colon transit time was defined as 
more than 72 h [17,18].
Statistical analyses
Relative risks were used to compare the frequencies of gastrointestinal symptoms. In order 
to be able to determine the confidence interval and estimate when the frequency of a 
symptom was 0 in one of the groups, one additional observation was added to that group 
with the symptom present. This leads to a slightly conservative estimate of the risk ratio and 
its confidence interval. Differences in mean constipation score were tested using the t-test. 
Ninety-five percent confidence intervals were calculated. 
RESULTS
Questionnaires
Of the 32 known genetically proven Dutch patients with DM2, two patients were excluded 
because they had co morbidity that could have influenced gastrointestinal motility, namely 
Sjögren’s syndrome and HIV infection. One DM2 patient refused to participate due to 
psychological problems with the diagnosis. The average age of the remaining 29 patients 
with DM2 was 55.5 years (range 27–75) and 23 (79%) were female. Twenty-nine adult-onset 
patients with DM1 and 87 healthy volunteers both matched for age and sex, also filled out the 
questionnaires (Table 5.1). Concerning dysphagia, abdominal pain, and constipation, there 
was a statistically significant higher frequency of these symptoms among patients with DM2 
compared to the healthy controls, as shown in Table 5.2. Moreover, the frequencies of these 
symptoms in DM2 were comparable to or even higher than in DM1, although not statistically 
significant. Mean constipation score for healthy controls was 6.1 (men: 5.6, women: 6.2), 
which corresponds to the mean of healthy controls of 6.0, published earlier [14]. Mean 
constipation score in DM2 was 9.1 (men: 8.8, women: 9.2), significantly higher than in healthy 
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controls, which means a higher presence of constipation in DM2 (Table 5.2). In general, 
gastrointestinal dysfunction was considered among the most disabling symptoms by 45% 
of patients with DM2. Use of laxatives was reported in six patients with DM2. Mean ages of 
patients with DM2 using laxatives and non-users were comparable (54.7 vs. 55.7 years). The 
constipation score was higher in patients with DM2 using laxatives (mean constipation score 
12.2) than in patients with DM2 not using them (mean constipation score 8.3).
Colon transit time
Colon transit time was measured in 18 patients with DM2. There was no significant difference 
in frequencies of gastrointestinal symptoms between patients with DM2 who underwent 
colon transit time measurement and patients with DM2 who did not. One of the 18 patients 
with DM2 continuously used laxatives during the study because of the severity of her 
constipation, and was excluded from further analysis. Colon transit time was delayed in 24% 
of the patients with DM2. The four patients with DM2 (one man, three women; mean age 61.0 
years) with increased colon transit time all belonged to different DM2 families. Mean age of 
the patients with DM2 with normal colon transit time was 56.0 years.
Table 5.1 Characteristics of patients with DM2, DM1 and controls
Characteristics DM2 DM1 Controls
N 29 29 87
Female sex (%) 23 (79%)  20 (69%) 69 (79%)
Mean age in years (range) 56 (27-75) 54 (29-75) 55 (24-80)
Abbreviations: DM2, myotonic dystrophy type 2; FMS, fibromyalgia syndrome; HC, healthy controls.
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DISCUSSION
In this prospective nationwide cross-sectional study, gastrointestinal symptoms were 
found to be highly prevalent in genetically proven patients with DM2. Their prevalence was 
comparable to that of patients with DM1. Dysphagia was present in about 50% of the 29 
patients with DM2 from 12 families, which is more than in a previous study of a DM2 family, 
where complaints of dysphagia and aspiration were described in three of the 22 patients 
with DM2 (14%) [9]. Other reports contained only single case observations [4,8]. Since the 
major complication of dysphagia is aspiration, dysphagia may be a problem that can lead 
to pneumonia. Pneumonia, together with cardiac arrhythmias, is known to be the most 
frequent cause of death in DM1 [19]. However, up until now, there has been no evidence of 
severe late stage dysphagia and pneumonia due to aspiration in patients with DM2 as is the 
case in adult-onset patients with DM1. Both abdominal pain and constipation were present 
in 62% of the patients with DM2. The mean constipation score of patients with DM2 was 9.1, 
which was significantly higher than in the control group (6.1). This confirms the presence 
of constipation in patients with DM2, which is also supported by an increased colon transit 
time in 24% of the patients with DM2. Several procedures have been used to measure colonic 
transit time (CTT), and different upper limits of normal CTT have been described, varying 
from 45 [15] to 72 h [17,18]. We defined a delayed CTT as more than 72 h, using the highest upper 
limit. For comparison, mean CTT among 73 controls was 36 ± 4 h described by Pemberton [18]. 
In the literature, we found only one study of a PROMM family where constipation was 
described earlier [8]. 
A point of criticism can be the uneven sex distribution in this study, because 79% of 
patients with DM2 are female. However, we found no correlation between the outcome 
measures (dysphagia, abdominal pain, and constipation) and sex, and no correlation was 
found between the constipation score and sex in patients with DM2. Colon transit time 
was delayed in four patients with DM2 (one man, three women). In summary, although the 
sex distribution is uneven in our DM2 group, the occurrence of gastrointestinal symptoms 
correlates to the existence of the DM2 mutation and not to sex.
Physicians can help most patients with constipation through lifestyle, dietary and 
pharmacological adjustments like osmotic laxative, along with supplementary fibres.  All this 
to avoid obstructive symptoms as mega colon, which has been described in DM1 and can 
lead to death [20]. As a treatment guideline for DM2, prescription of tramadol and other opiates 
has to be avoided because of the frequent negative side effects on gastrointestinal motility. 
In conclusion, awareness of gastrointestinal dysfunction as part of the clinical picture of DM2 
may lead to early recognition of these symptoms, so adequate treatment can be provided. 
Further research on the pathophysiology of these gastrointestinal symptoms is warranted.
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ABSTRACT
Background. The phenotype of myotonic dystrophy type 2 (DM2) shows similarities as well 
as differences to that of myotonic dystrophy type 1 (DM1). Dysphagia, a predominant feature 
in DM1, has not yet been examined in DM2. In a recent nationwide questionnaire survey of 
gastrointestinal symptoms in DM2, 12 out of 29 patients with DM2 reported to have difficulty 
in swallowing for solid food. 
Objective. The aim of the study was to investigate the presence of dysphagia in patients with 
genetically proven DM2 who reported difficulty in swallowing at the questionnaire survey.
Methods. Swallowing function and fiberoptic endoscopic evaluation of swallowing (FEES) 
were examined by a speech therapist and otorhinolaryngologist respectively.
Results. In patients with DM2 who reported difficulty in swallowing the presence of dysphagia 
could be confirmed (clinically in 100%, by FEES in 88%). A correlation exists between 
Dysphagia Outcome and Severity Score (DOSS) and age (P = 0.05). None of the patients was 
short weight, and none of the patients had suffered aspiration pneumonia in the past. 
Conclusion. Dysphagia is present among patients with DM2 and is more severe in older 
patients. However, dysphagia is generally mild, and do not lead to short weight, or aspiration 
pneumonia. 
Abbreviations: BMI, body mass index; CNBP, cellular nucleic acid binding protein; DM1, myotonic dystrophy type 1; 
DM2, myotonic dystrophy type 2; DOSS, Dysphagia Outcome and Severity Score; GSQ, gastrointestinal symptoms 
questionnaire; FEES, fiberoptic endoscopic evaluation of swallowing; NA, not assessed; PROMM, proximal myotonic 
myopathy; SD, standard deviation; ZNF9, zinc finger protein 9.
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INTRODUCTION
Myotonic dystrophy type 2 (DM2, MIM 602668) is a dominantly inherited multisystem disorder
characterized by progressive proximal muscle weakness, myotonia, early-onset cataract, 
cardiac arrhythmia, and muscle pain. DM2, earlier known as proximal myotonic myopathy 
(PROMM), is caused by a CCTG expansion in intron 1 of the ZNF9 gene on chromosome 3q21, 
currently known as the CNBP gene [1]. The clinical picture of DM2 shows similarities as well as 
differences to that of myotonic dystrophy type 1 (DM1). Shared core features are autosomal 
dominant inheritance, muscle weakness, myotonia, early-onset cataract, and multiorgan 
involvement with cardiac conduction defects, insulin resistance, and gonadal atrophy. 
Notably absent is a congenital form of DM2, and evidence of anticipation is less striking than 
in DM1, while muscle pain is more prominent in DM2 [2].
Dysphagia, a predominant and potentially life-threatening feature in DM1, has not 
yet been examined in DM2. Dysphagia has been described in a few scattered PROMM and 
DM2 case reports [3-5]. We recently performed a prospective nationwide study to explore the 
presence and characteristics of gastrointestinal dysfunction in patients with DM2 [6]. In that 
validated questionnaire survey 12 out of 29 patients reported to have swallowing difficulties 
for solid food.
In this study, we set out to assess oropharyngeal swallowing in patients with genetically 
proven DM2 who reported difficulty in swallowing  at the questionnaire survey in order to 
objectify this symptom. 
PATIENTS AND METHODS
Patients
In a recently performed nationwide survey genetically proven patients with DM2 filled out the 
Dutch Gastrointestinal Symptoms Questionnaire (GSQ) [6]. This standardized questionnaire 
covers symptoms from all parts of the gastrointestinal tract and contains questions about 
the severity of gastrointestinal symptoms during the last 4 weeks [7]. All patients with DM2 
who reported swallowing difficulties for solid food at the GSQ were recruited for this study. 
Exclusion criterion for participating was pregnancy because of its increased risk of pulmonary 
aspiration.
Patients were approached for additional information about their medical history and 
the body mass index (BMI) was calculated for all patients. The medical ethics committee 
approved the protocol and all patients gave written consent.
Methods
All patients with DM2 were clinically investigated by an experienced speech therapist in 
neuromuscular disorders. Eight patients with DM2 gave additional informed consent to 
fiberoptic endoscopic evaluation of swallowing (FEES).
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Clinical investigation
An orofacial examination was performed as earlier described[8]. In short, the clinical 
examination included: assessment of the strength of the jaws, lips, and tongue; weakness 
was scored as mild, moderate or severe; assessment of myotonia of the masseter muscles 
and tongue; myotonia was scored as absent or present; observation while eating solid food 
(a biscuit); a timed test of swallowing [9].
Fiberoptic endoscopic evaluation of swallowing
Fiberoptic endoscopic evaluation of swallowing (FEES) is a valid and exceptionally safe 
technique for assessing preswallow anatomy and physiology in order to objectively evaluate 
patients with dysphagia [10]. Diagnosis of oropharyngeal dysphagia was determined by 
premature spillage, pharyngeal residue, laryngeal penetration and aspiration. 
Dysphagia Outcome and Severity Score (DOSS)
All symptoms were scored with the DOSS, a reliable scale developed to rate the functional 
severity of dysphagia based on objective assessment [11]. Scores range from 1 (severe 
oropharyngeal dysphagia necessitating non-oral nutrition) to 7 (normal in all situations). 
Oropharyngeal dysphagia was diagnosed when a patient was scored on level 1 to 6.
Statistical analysis
We used the Pearson partial correlation coefficient for calculating correlations, and 
considered P < 0.05 significant.
RESULTS
Clinical investigation
Twelve patients with DM2 complaining of swallowing difficulties for solid food were recruited. 
Ten (from eight different families) of the 12 patients took part in the study, two patients 
refused to participate. Mean age was 58.0 years (SD 11.6) and mean age of disease onset 
was 26.7 years (SD 13.0). Mean BMI in patients with DM2 was 25.1 (SD 4.0), none of the patients 
had short weight (BMI < 18.5). None of the patients had suffered aspiration pneumonia 
in the past. 
Seven patients showed signs of weakness of the jaws, lips, or tongue. None of the 
patients showed myotonia of the jaws or tongue.
Evaluation of eating showed slowness in all patients with DM2, and frequent swallowing 
in nine. Six patients demonstrated a slightly flexed position of the head upon swallowing. 
Coughing and wet phonation, indicating possible residue, penetration or aspiration, were 
observed in five patients. 
A timed test of swallowing showed the swallowing speed (average volume per swallow) 
to be too low, that is to say lower than normal, in four patients (patients 3, 4, 8 and 9). Five 
other patients (patients 1, 5, 6, 7 and 10) drank more slowly than the mean swallowing speed 
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of age and sex matched healthy controls from literature, but still fell within normal values [12] 
(Table 6.1).
Fiberoptic endoscopic evaluation of swallowing 
Of the eight patients assessed with FEES, one exhibited normal swallowing and seven (88%) 
exhibited dysphagia; residue of solid food in seven cases (88%), residue of milk in six cases 
(75%), and residue of saliva was observed in two cases (25%). Spillage of milk was revealed in 
two patients (25%), spillage of solid food was detected in one patient (13%). No penetration 
or aspiration of milk or solid food was detected (Table 6.1).
Dysphagia Outcome and Severity Score
DOSS score was found to be abnormal in all patients with DM2, ranging in severity from “mild-
moderate” (score 4) to “within functional limits” (score 6). DOSS and age correlated in patients 
(rho -0.66, P = 0.05), age at disease onset and swallowing speed correlated significantly 
(rho -0.68, P = 0.04). There was no correlation between DOSS score and age at disease onset 
or disease duration.
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Table 6.1. Patient characteristics and results of clinical investigation, FEES and DOSS
Pt 1 Pt 2 Pt 3 Pt 4 Pt 5 Pt 6 Pt 7 Pt 8 Pt 9 Pt 10
Characteristic
Sex F F M M F F F F F F
Age, yrs 68 55 37 64 71 72 55 62 46 48
Age at disease onset, yrs 43 18 27 52 22 12 10 28 26 29
Orofacial examination
Weakness of jaws – – – – – ± – – – –
Weakness of lips – – – ± – ± – – ± –
Weakness of tongue ± ± – ± ± ± – ± – –
Timed test of swallowing
Swallowing speed in mL/s 8 14 16 11 11 12 11 4 8 9
Mean (SD) reference value 
in mL/s r
12.3
(4.9)
12.3 
(4.9)
24.8 
(7.8)
18.7 
(5.2)
12.3 
(4.9)
12.3 
(4.9)
12.3 
(4.9)
12.3 
(4.9)
13.6 
(4.8)
13.6 
(4.8)
Evaluation of eating
Slowness ++ + + + + + ++ ++ + ±
Frequent swallowing + + + + + + – + + +
Adapting head position + + + – – + – + – +
Coughing, wet phonation + – + – – + – – + +
FEES NA NA
Deviant anatomy – + – – – – – –
Residue of saliva – + – – – – – +
Spillage of milk + – – – + – – –
Spillage of biscuit + – – – – – – –
Residue of milk + + + + – + – +
Residue of biscuit + + + + + + – +
Penetration of milk – – – – – – – –
Penetration of biscuit – – – – – – – –
Aspiration of milk – – – – – – – –
Aspiration of biscuit – – – – – – – –
DOSS 4 4 5 4 4 4 5 4 6 4
Abbreviations: Pt, patient; SD, standard deviation; FEES, fiberoptic endoscopic evaluation of swallowing; DOSS, 
Dysphagia Outcome and Severity Score (7 = normal, 6 = within functional limits, 5 = mild, 4 = mild-moderate, 
3 = moderate, 2 = moderate-severe, 1 = severe dysphagia) [11]; NA, not assessed.
(-) absent; (±) minimal signs; (+) clear signs; (++) = severe
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DISCUSSION
In patients with DM2 who reported difficulties in swallowing the presence of dysphagia 
could be confirmed (clinically in 100%, by FEES in 88%). Dysphagia was more pronounced 
in older patients with DM2. None of the 10 patients had suffered aspiration pneumonia in 
the past, and no patient had short weight. These findings are in correspondence with the 
results that dysphagia is generally mild. These results give little or no indication of the 
underlying pathology of swallowing difficulties. Weakness of the oropharyngeal muscles as 
well as subclinical myotonia may play a role. In DM1 both muscle weakness and myotonia 
encountered in oropharyngeal muscles play an important part in the oral and the pharyngeal 
phases of swallowing dysfunction [13]. In our group, minimal weakness of the orofacial muscles 
but no myotonia was observed clinically. Electrophysiological evaluation of swallowing is 
necessary to show the possible existence and frequency of subclinical electrophysiological 
abnormalities in oropharyngeal swallowing and may clarify the mechanisms of dysphagia. 
Recognition of dysphagia may have implications for the management of patients with DM2 
and for recommendations regarding the prognosis. Firstly, patients with DM2 with dysphagia 
may benefit from conservative interventions such as speech therapy and modification of food 
consistency. Secondly, since the major complication of dysphagia is aspiration, dysphagia 
may be a problem that can lead to pneumonia. We found, however, no evidence of severe 
late stage dysphagia and pneumonia due to aspiration in patients with DM2 as is the case in 
patients with adult-onset DM1.
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ABSTRACT
Objective. To systematically assess auditory characteristics of a large cohort of patients with 
genetically confirmed myotonic dystrophy type 2 (DM2).
Methods. Patients with DM2 were included prospectively in an international cross-sectional 
study. A structured interview about hearing symptoms was held. Thereafter, standardized 
otologic examination, pure tone audiometry (PTA; 0.25, 0.5, 1, 2, 4 and 8 kHz), speech 
audiometry, tympanometry, acoustic middle-ear muscle reflexes, and brainstem auditory 
evoked potentials (BAEP) were performed. The ISO 7029 standard was used to compare the 
PTA results with established hearing thresholds of the general population according to sex 
and age.
Results. Thirty-one Dutch and 25 French patients with DM2 (61% female) were included with 
a mean age of 57 years (range 31-78). The median hearing threshold of the DM2 cohort was 
higher for all measured frequencies, compared to the 50th percentile of normal (P < 0.001). 
Hearing impairment was mild in 39%, moderate in 21% and severe in 2% of patients with 
DM2. The absence of an air-bone gap with PTA, concordant results of speech audiometry 
with PTA and normal findings of BAEP suggest that the sensorineural hearing impairment is 
located in the cochlea. A significant correlation was found between hearing impairment and 
age, even when corrected for presbycusis. 
Conclusion. Cochlear sensorineural hearing impairment is a frequent symptom in patients 
with DM2, suggesting an early presbycusis. Therefore, we recommend informing about 
hearing impairment and readily performing audiometry when hearing impairment is 
suspected in order to propose early hearing rehabilitation with hearing aids when indicated.
Abbreviations: BAEP, brainstem auditory evoked potential; CNBP, cellular nucleic acid binding protein; dB HL, 
decibel hearing level; DFNA, deafness, autosomal dominant; DM1, myotonic dystrophy type 1; DM2, myotonic 
dystrophy type 2; FSHD, facioscapulohumeral dystrophy; HI, hearing impairment; ISO, International Organization for 
Standardization; kHz, kilohertz; LGMD, limb girdle muscular dystrophy; mRS, modified Rankin Scale; PMD, proximal 
myotonic dystrophy; PROMM, proximal myotonic myopathy; PTA, pure tone audiometry; SD, standard deviation; 
ZNF9, zinc finger protein 9.
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INTRODUCTION
Myotonic dystrophy type 2 (DM2), formerly known as proximal myotonic myopathy (PROMM), 
is a dominantly inherited multisystem disorder with a heterogeneous phenotype, caused by 
a CCTG expansion in intron 1 of the CNBP gene on chromosome 3q21.3 [1]. The mean age of 
onset of symptoms is 34 years [2]. Important neuromuscular symptoms are proximal muscle 
weakness, myotonia and pain. Other organs are prominently involved, with frequent early-
onset cataract, cardiac conduction abnormalities, gastrointestinal symptoms, endocrine 
changes and central nervous system symptoms [2-5]. 
There are many similarities between DM2 and myotonic dystrophy type 1 (DM1) [6]. In 
DM1, hearing impairment is a well-known feature [7-11]. In clinical practice, we observed several 
patients with DM2 complaining of hearing impairment, sometimes wearing or requiring 
hearing aids after evaluation. Although hearing impairment has been reported in several 
cases with DM2, it has never been systematically evaluated [12-18]. To date, hearing impairment 
does not belong to the classical description of DM2. However, to optimize guidance and 
treatment of patients with DM2 and to learn more about its pathophysiology, it is important 
to explore auditory function in a larger DM2 cohort than family reports. 
We hypothesized that there is a high prevalence of hearing impairment in patients with 
DM2. The aim of the present international study was to systematically assess the presence 
and characteristics of hearing impairment in a large population of patients with genetically 
confirmed DM2 and to establish whether hearing impairment is part of the DM2 clinical 
phenotype.
PATIENTS AND METHODS
Patients
All patients with DM2 in the Netherlands (n = 54) and in the Myology Institute in Paris (n = 26) 
were invited to participate. Inclusion criteria were genetically confirmed DM2 and an age > 17 
years. The CCTG-expansion in the CNBP gene had been detected using standard methods [19]. 
No repeat size was measured, as no clear correlation has been established between repeat 
size and clinical symptoms [1,2,20]. In case of a history of otological surgery, the concerning ear 
was excluded. 
Standard protocol approvals, registrations, and patient consents
The study was carried out according to the Helsinki Declaration and all patients provided 
written informed consent. Both the Dutch and French local ethics committee approved the 
study (CMO Arnhem-Nijmegen, 2013/019; ERB Paris VI, A01741-44).
Methods
Medical history and general features were recorded during the visit, including the presence 
of cataract, diabetes mellitus and cardiac abnormalities. Age at onset was documented and 
the six-point modified Rankin Scale (mRS) was used to indicate the severity of the disease [21]. 
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An otorhinolaryngological structured interview and examination was conducted by an 
otologist, including questions about subjective hearing impairment and its onset, associated 
symptoms, otological history, previous noise exposure and the use of ototoxic drugs 
(Supplement 1). To finish, pure tone audiometry (PTA), speech audiometry, tympanometry, 
acoustic middle-ear muscle reflexes and brainstem auditory evoked potentials (BAEP) were 
performed systematically to objectively qualify and quantify hearing impairment (Figure 7.1).
Figure 7.1 Hearing tests in relation to the ear anatomy 
Sensorineural HIConductive HI
Acoustic reflex
Tympanometry BAEP
Pure tone audiometry (PTA) measures the hearing thresholds for 6 frequencies (0.25, 0.5, 1, 2, 4 and 8 kHz). The 
difference between air and bone conduction according to the PTA, and the results of the speech audiometry 
differentiate between conductive and sensorineural hearing impairment (HI). Tympanometry assesses the 
function of the tympanic membrane and middle ear. The acoustic middle ear reflex measures the function of 
the stapedius muscle, stapes and retrocochlear function. Brainstem auditory evoked potential (BAEP) evaluates 
retrocochlear function. 
Reprinted with permission from Wenig by permission of Elsevier © 2016 [22].
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Pure tone audiometry (PTA)
With PTA, both air and bone conduction hearing thresholds in decibels hearing level (dB HL) 
were determined at 0.25, 0.5, 1, 2, 4 and 8 kHz. It was carried out in a sound treated room, 
calibrated according to ISO 389 and measured according to the ISO 8253-1 standard [23,24]. 
Hearing impairment was defined as asymmetrical when a difference of more than 10 dB HL 
was found in at least two frequencies [25]. The difference between air and bone conduction 
(air-bone gap) was calculated for the mean of 0.5, 1 and 2 kHz to differentiate between 
conductive and sensorineural hearing impairment [25]. The mean of the hearing thresholds of 
0.5, 1, 2 and 4 kHz of the best ear was used to define the severity of hearing impairment (none: 
0-20 dB, mild: 21-40 dB, moderate 41-70 dB and severe > 70 dB) [24].
Speech audiometry
Speech audiometry was performed to determine speech intelligibility and discrimination 
and word recognition abilities. It was performed in a sound treated room, using a standard 
monosyllabic (consonant-vowel-consonant) Dutch or French word list, respectively. The 
maximum monaural phoneme recognition scores (percentage correct recognition) were 
evaluated for each ear from a performance-intensity plot constructed for monaurally 
presented words. 
Tympanometry and acoustic middle ear muscle reflexes
Tympanograms and acoustic middle ear muscle reflexes were recorded with an impedance 
audiometer AT235. The results of the tympanometry were categorized according to the 
modified classification of Jerger as type A (normal middle ear), B (decreased mobility 
tympanic membrane, consistent with middle ear pathology), C1 (moderate negative middle 
ear pressure) or C2 (negative middle ear pressure with retracted tympanic membrane) [26].
The acoustic middle ear muscle reflex is the involuntary muscle contraction of the 
stapedius muscle in response to a high-intensity sound stimulus, and is normally present 
bilaterally. This reflex was elicited at 1 kHz, measured at the peak tympanometric pressure. 
A broadband noise and a reflex-activating stimulus were provided ipsilaterally, starting at 85 
dB HL with a maximum of 110 dB HL. 
Brainstem Auditory Evoked Potentials
BAEPs were obtained with a Keypoint (Medtronic, Langhorne, PA) and measured to assess 
retrocochlear function (acoustic nerve and brainstem). Monoaural click stimuli with a 
duration of 50 μs were delivered through shielded earphones with a frequency of 10 Hz and 
intensity of 70-90 dB HL. Both ears were stimulated separately. Masking of the contralateral 
ear was accomplished by noise with an intensity of 20 dB below click intensity. The bandpass 
filters were set at 100-3,000 Hz. At least two trials of 1,000 clicks were recorded to assess 
reproducibility. The BAEP I-V interpeak latency was recorded and considered abnormal 
above the upper limit of normal based on the 95% sex- and age-related confidence limits. All 
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BAEPs were assessed for reproducibility and analyzed by 2 or 3 trained neurophysiologists or 
otologists. The opinion of the majority was taken as the definite conclusion. 
Statistics
SPSS version 21 was used for statistical analysis. All included ears were used for analysis. 
Normality of variables was evaluated by histograms and the Shapiro-Wilk test. P < 0.05 was 
considered statistically significant. Considering the observational study design, we did not 
correct for multiple testing.
The ISO 7029 standard contains normal values for hearing thresholds by air conduction 
(PTA) as a function of sex and age for otologically normal persons, with exclusion of 
participants with undue noise exposure [27]. It was used to determine the individual 50th and 
95th percentile threshold values (P50 and P95) in relation to sex and age for all measured 
frequencies [7,28]. Thresholds beyond the P95 value were considered abnormal. Participants 
with noise exposure – the definition based on the expert opinion of the otolaryngologist – 
were excluded for comparison with the ISO 7029 standard. 
The excess in hearing impairment was calculated for each participant by subtracting 
the P50 threshold for the same sex and age from the established hearing threshold at a 
given frequency [7,28]. The sign test was used to calculate the difference between the excess 
in hearing impairment and the P50 for each frequency, both for all included ears and for the 
best ear of each participant only, to correct for the possible influences of exogenous and 
endogenous factors. The best ear was defined as the ear with the lowest hearing threshold 
of the mean of the frequencies 0.5, 1, 2 and 4 kHz [25]. Missing data in tympanometry, acoustic 
middle ear reflexes and BAEP due to planning difficulties are addressed. 
RESULTS
Patients
Between September 2013 and March 2016, 56 patients with DM2 were enrolled in this study, 
respectively; 31 Dutch patients from 18 different families and 25 unrelated French patients (in 
total 75% unrelated). Two ears were excluded: 1 from a patient with a history of a vestibular 
schwannoma and another from a patient who was Barany deaf unilaterally due to several ear 
infections and had had a meatoplasty. Two included patients were diagnosed with cerebellar 
benign tumors (meningioma and hemangioblastoma).
Demographic features and symptoms of hearing impairment are shown in Table 7.1. 
Only two patients received an ototoxic drug (respectively, quinine for a few weeks and 
cyclosporine). Two patients had meningitis in their childhood, with no hearing damage 
observed afterwards. Sixteen patients were exposed to noise (14 work-related, 1 orchestra 
member, and 1 frequently visited discotheques). Three patients reported hearing impairment 
as one of the first symptoms (5%). Otologic examination was normal in all patients, except 
unilateral retraction of the tympanic membrane in 1 patient and unilateral fluid behind the 
tympanic membrane in another patient.
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Table 7.1 Demographic features and symptoms of hearing impairment
Feature DM2
n = 56
Demographic features
Female sex 34 (61)
Age (yrs)   Mean (SD) 57 (11.8)
   Range 31-78
Age of disease onset (yrs) Mean (SD) 39 (13.4)
   Range 12-71
mRS, median (P25-P75) 2 (2-3)
Cataract 36 (64)
Surgery 22 (39)
Diabetes mellitus 8 (14)
Arrhythmia 13 (25)
Symptoms of hearing impairment
Hearing impairment 42 (75)
   Slowly progressive 39 (93)
   Sudden* 3 (7)
Age at onset hearing impairment (yrs)**
Mean (SD) 51 (10.6)
Range 26-73
Hearing aid*** 12 (21)
Noise exposure 16 (29)
Otitis in history 11 (20)
Tinnitus 18 (32)
Vertigo 13 (23)
Hearing impairment by PTA^
None (0-20 dB) 21 (38)
Mild (21-40 dB) 22 (39)
Moderate (41-70 dB) 12 (21)
Severe (>71 dB) 1 (2)
Abbreviations: DM2, myotonic dystrophy type 2; SD, standard deviation; mRS, modified Rankin Scale; PTA, pure 
tone audiometry. Data are n (%) unless otherwise specified.
*Both patients with vestibular schwannoma and meatoplasty had acute hearing impairment unilaterally, one 
other patient had unilateral sudden deafness, which recovered completely. 
**32 patients; 2 did not know the age at onset of hearing impairment; in 8 patients it is unknown.
***Median age 65 (range 37-76 years), in 10 (83%) patients bilaterally 
^ Mean of 0.5, 1, 2 and 4 kHz of the best ear
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Pure tone audiograms (n = 56, 110 ears)
The threshold values were symmetrical (≤ 10 dB HL) between right and left in 39 patients 
(72%). An asymmetry was observed for two frequencies in 10 patients (maximum difference 
25 dB HL), for 3 frequencies in 2 patient, for 4 frequencies in 3 patients (maximum difference 
35 dB HL) and, in 1 patient all frequencies differed more than 10 dB HL.
Bone conduction audiometry was performed in 33 patients (62 ears; in 4 patients bone 
conduction was only measured unilaterally given the symmetrical air conduction results 
and absent air-bone gap). Ninety-eight percent (61 ears) had no air-bone gap. One patient 
had an air-bone gap of 25 dB HL on the right. He had also had asymmetric air conduction 
thresholds, and fluid behind the right tympanic membrane, probably suffering from mixed 
hearing impairment.
Mean hearing threshold level (average of 0.5, 1, 2 and 4 kHz) was more than 30 dB in at 
least one ear in 25 patients (44.6%), indicative for the use of hearings aids [29].
Sixteen patients had a history of noise exposure. Patients with and without noise 
exposure were compared by calculating the excess in hearing impairment for each frequency. 
A difference was found for 2 kHz only (P = 0.02, Mann-Whitney U test) in favor of patients 
without noise exposure, but not for the frequencies 0.25, 0.5, 1, 4 and 8 kHz (P = 0.71, 0.90, 
0.31, 0.17 and 0.73, respectively). 
Pure-tone audiograms compared to ISO 7029 (n = 40, 78 ears)
In 87% of all included ears (n = 40, 78 ears, 16 patients with noise exposure excluded) at least 
1 of the frequencies was outside the P95 of normal (1 frequency in 22%, 2 frequencies in 
24%, 3 frequencies in 10%, 4 frequencies in 20%, 5 frequencies in 16% and all frequencies 
in 9%; Figure 7.2). All 8 patients younger than 40 years (median 32, range 31-35) had at 
least 1 hearing thresholds outside the P95 of normal. Median hearing impairment for each 
Table 7.2. Results of pure tone audiometry
Frequency 
(kHz)
Hearing threshold 
(dB) all ears
n = 78
Hearing threshold (dB) 
best ear
n = 40
P50
ISO 7029 
values
P-value*
0.25 20 (15-30) 20 (10-25) 4.5 (3-6) < 0.001
0.5 20 (15-30) 20 (10-30) 5 (4-7) < 0.001
1 15 (10-35) 15 (10-32.5) 5.5 (4-8) < 0.001
2 20 (10-40) 17.5 (10-37.5) 10 (6-14) < 0.001
4 32.5 (20-50) 27.5 (15-50) 15.5 (9-24) < 0.001
8 60 (40-80) 55 (32.5-77.5) 24.5 (15-36) < 0.001
Abbreviations: kHz, kilohertz; dB, decibel; ISO, international organization of standardization.
Median (P25-P75) hearing impairment for each frequency, for ‘all included ears’ and ‘best ears’. The P50 was 
calculated according to the ISO 7029 for each participant of the same sex and age, the median of all participants 
is shown. The signed-rank test was used to calculate the difference between the median of the DM2 population 
and the corresponding P50, according to the ISO 7029 standard.
*For both ‘all ears’ and ‘best ears’
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frequency is presented in Table 7.2 and Figure 7.3. For both all included ears and the best ear 
only, median hearing impairment was higher than the corresponding P50 for all frequencies 
(P < 0.001, sign test).
Figure 7.4 demonstrates the correlation between excess in hearing impairment and 
age (spearman’s rho 0.514, P < 0.001). Also, a correlation was found between excess in hearing 
impairment and modified Rankin Scale (spearman’s rho 0.271, P = 0.016).
Figure 7.2 Percentage of ears with corresponding percentile according to the ISO 7029 standard 
for same age and sex for each frequency  
For each frequency, the percentage of ears with corresponding percentile is demonstrated, according to the ISO 
7029 [27]. For example, 56% of the ears has a hearing threshold for 250 Hz above P95.
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Figure 7.3 Pure tone audiometry with median hearing threshold of each frequency for both ears   
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Abbreviations: kHz, kilohertz; dB, decibel; DM2, myotonic dystrophy type 2. 
The median hearing threshold in decibel is shown for each frequency in patients with DM2 (red line), as well as 
the P50 and P95 for healthy controls of the same age and sex (black lines), according to the ISO 7029.
Speech audiometry (n = 56, 110 ears)
Speech recognition was normal in 90% (104 ears). In 5 patients (6 ears) speech recognition 
was below 90% and all these cases showed severe hearing impairment (unilateral loss of 
speech recognition of 88%, 85%, 85%, 55% and bilateral 75% and 30%, respectively). 
Tympanometry and acoustic middle-ear muscle reflexes (n = 51, 101 ears)
Tympanometry was normal in 94% of cases. One patient with frequent otitis in the past and 
a labyrinthitis had a unilateral type B tympanogram. Two patients had a bilateral type C 
tympanogram, 1 patient had a retracted tympanic membrane on the left, the other patient 
had fluid behind the right tympanic membrane and suffered from severe hearing impairment. 
Acoustic reflexes were absent in 8 patients (four bilateral, four unilateral), probably due to the 
severe hearing impairment in all but 2 cases.
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Figure 7.4 Correlation between age and the excess in hearing impairment   
Excess in hearing impairment of each ear is demonstrated by subtracting the P50 for the same sex and age from 
the established thresholds, for the mean of 0.5, 1, 2, 4 kHz (n = 78), plotted against age. Spearman’s rho 0.514, P 
< 0.001. The equally colored participants are related and from different generations.
BAEP (n = 51, 102 ears)
All BAEPs were normal, except for one, showing a prolonged latency of the I-V complex on the 
left. In 14% no reproducible response was found. 
DISCUSSION
We present the results of a comprehensive study on audiological characteristics in a large 
international cohort of patients with genetically confirmed DM2 from multiple families. Hearing 
impairment was reported by 75% of the patients, and PTA results clearly established that 
hearing impairment is a common symptom in patients with DM2. Furthermore, the absence 
of an air bone gap in PTA, concordant speech audiometry to PTA, normal tympanometry and 
normal BAEPs strongly suggest that the origin of the sensorineural hearing impairment is 
located in the cochlea.
Hearing impairment has been reported in several case reports of proximal myotonic 
myopathy (PROMM), proximal myotonic dystrophy (PMD) and DM2, including in different 
familial cases [13,15-18,30]. Sensorineural deafness was described in 40% of 60 patients with DM2, 
CHAPTER 7
108
although the severity was not otherwise specified [14]. Also, 6 out of 22 patients with DM2 were 
reported with hearing impairment before the age of 60 years [12]. The results of the PTA of 
the present study confirm and extend these reports, and establish the high prevalence of 
hearing impairment in patients with DM2, while the additional investigations indicate the 
origin in the cochlea.
Sensorineural hearing impairment is also an established feature of DM1, a disorder that 
shares many clinical similarities to DM2 [12]. In DM1, a prominent hearing impairment of the 
higher frequencies has been found, implicating a precocious auditory dysfunction similar 
to an early presbycusis [7-11]. Interestingly, in the present study, more patients had abnormal 
hearing thresholds (> P95) on the lower frequencies (0.25 and 0.5 kHz) compared to the higher 
frequencies. However, hearing impairment was more severe at the higher frequencies (4 and 
8 kHz). Moreover, a significant correlation was found between hearing impairment and age, 
even when corrected for presbycusis. Hearing impairment in DM2 is present in all frequencies 
and suggests early presbycusis like in DM1. It would be of interest to repeat the present study 
in a large group of DM1 patients to compare the results. Moreover, an interesting additional 
objective test is otoacoustic emission, to screen for the presence of hearing impairment and 
to confirm the localization in the cochlea [9].  
The finding of early presbycusis is of interest for the hypothesis that many symptoms 
of myotonic dystrophies can be viewed as a result of premature aging, such as muscle 
weakness, cataract, baldness, and cognitive decline [31]. Both DM2 and DM1 are considered 
spliceopathies, meaning that the repeat expansion leads to an alteration of alternative 
splicing [20]. The current investigations locate the origin of hearing impairment in DM2 in the 
cochlea, as in DM1 [8,9]. Particularly vulnerable for injury in the cochlea are the stria vascularis 
and inner and outer hair cells; these sites are probably also involved in presbycusis [32]. 
Malfunctioning of the outer hair cells may play a role in DM1, due to somatic electromotility 
alteration that affects voltage-dependent shape changes in DM1 [9]. Accordingly, cochlear 
dysfunction may be linked to a misregulation of an alternative splicing of ionic channels or 
cytoskeletal myosin proteins able to interact with membrane channels in outer hair cells [33]. 
The same mechanism may apply to DM2, and could explain why both DM1 and DM2 show 
sensorineural hearing impairment.
Another interesting possible explanation is the finding of a locus for hearing impairment 
(DFNA18) immediately adjacent to the DM2 locus [34]. A family was described with autosomal 
dominant nonsyndromal progressive hearing impairment with an onset in the first decade of 
life, affecting the higher frequencies first and the middle and lower frequencies in the following 
decades. The DFNA18 locus has also been linked to age-related hearing impairment [35]. In 
both DM1 and DM2, the repeat expansion influences the expression of neighboring genes [32,36]. 
Perhaps this locus for hearing impairment is influenced by the repeat expansion of the CNBP 
gene. An autosomal dominant locus for hearing impairment has been found close to the DM1 
locus as well (DFNA4) [37].
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Acoustic middle ear reflexes were absent in 8 patients. Perhaps this is caused by the 
severe hearing impairment in these patients. However, this could also be explained by 
weakness of the stapedius muscle as part of DM2. 
In DM1, the symptoms may worsen with from one generation to the next one, a well-
known mechanism called anticipation that also concerns hearing impairment [7]. Anticipation 
does not seem to play a role in DM2, or at least is very rare [2,38]. In this study, no evidence of 
anticipation for hearing impairment was found. Indeed, the excess in hearing impairment was 
worse in the older generation than the younger generation in 3 of 4 related family members.
While there is no causal treatment for DM2, the finding of hearing impairment as part of 
the clinical picture is important for daily clinical practice to treat patients symptomatically. 
Patients with DM2 should be asked if they experience any hearing impairment and be informed 
about the risk of early presbycusis. PTA should be performed readily. Furthermore, DM2 may 
be added to the differential diagnosis of the combination of proximal muscle weakness 
and hearing impairment, also associated with mitochondrial myopathies (both adult-onset 
slowly progressive mild to moderate sensorineural hearing impairment as well as sudden-
onset hearing impairment), facioscapulohumeral dystrophy (adult-onset sensorineural 
hearing impairment as well as child-onset progressive high frequency hearing impairment 
in patients with a genetic small EcoRI/bInI fragment), and occasionally, limb girdle muscle 
dystrophies (mild to moderate hearing impairment in patients with LGMD2D) [39-43]. 
Strengths of the present international study are the large cohort of patients with DM2 
and extensive hearing tests. Nonrespondent bias of the Dutch patients may have affected the 
results as the participants may not be representative for the whole Dutch cohort, although 
almost all invited French patients participated. A limitation is the cross-sectional study 
design; it would be of interest to investigate whether hearing impairment is already present 
when DM2 is diagnosed. All ears were included to enlarge statistical power. However, PTA was 
also calculated for only the best ear of each participant as 2 ears are not entirely independent. 
The same significant differences were found when compared to the P50.
The present study distinctly established that hearing impairment is a frequent symptom 
in patients with DM2. Hearing impairment was mild in 39%, moderate in 21%, and severe 
in 2% of patients. All hearing tests performed suggest a sensorineural hearing impairment 
due to cochlear damage evoking a possible early presbycusis. Clinicians should inform 
patients with DM2 about the risk of hearing impairment, and readily perform audiometry 
and prescribe hearings aids when indicated.
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SUPPLEMENT 7.1 OTORHINOLARYNGOLOGICAL STRUCTURED INTERVIEW 
• Do you suffer from hearing impairment? If yes:
• Left, right of bilateral?
• Since when have you been experiencing hearing impairment?
• Did it evolve suddenly or slowly progress?
• Do you have a history of exposure to loud noises?
• Did you ever attend an otolaryngologist? If yes: where?
• Was an audiometry performed in the past?
• Do you have a hearing aid? If yes:
• Left, right or bilateral?
• Since when?
• What kind of hearing aid?
• Did you have recurrent infections of the ear in the past?
• Did you have surgery on your ear(s) in the past?
• Did you have a meningitis in the past?
• Do you have tinnitus? If yes:
• Left, right or bilateral?
• Since when?
• Do you have vertigo? If yes:
• Since when?
• Is this paroxysmal of continuous?
• Do you tend to fall?
• Are there any family members with hearing impairment?  
If yes: who (parents, grandparents, brothers/sisters, children. Do any of them have 
DM2?)
• What kind of medicine do you use exactly?
• Did you ever use quinine? 

Part III
Discussion and summary

8.
General discussion
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Abbreviations: ACR, American College of Rheumatology; CK, creatine kinase; CNBP, cellular nucleic acid binding 
protein; DFNA, deafness, autosomal dominant; DM1, myotonic dystrophy type 1; DM2, myotonic dystrophy type 2; 
EMG, electromyography; ENMC, European Neuromuscular Centre; FEES, fiberoptic endoscopic evaluation of 
swallowing; FMS, fibromyalgia syndrome; ICD-9, international classification of disease, version 9; LGMD, limb girdle 
muscular dystrophy; n-of-1, single patient trial; PPT, pressure pain threshold; PROMM, proximal myotonic myopathy; 
SCN4A, sodium channel, voltage-gated, type IV, alpha protein gene; SD, standard deviation; SF-36, 36 item short 
form health survey; TSH, thyroid stimulating hormone; VAS, visual analogue scale.
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GENERAL DISCUSSION
Most of our research questions were formulated on the basis of our experiences in daily 
clinical practice. We sought collaboration with several medical specialists outside our own 
field of expertise and together we designed the study protocols. In this general discussion 
the results are compared to recent observations in the literature and the implications and 
relevance of our findings for daily clinical practise will be discussed.  
Part I covers the differential diagnosis of fibromyalgia syndrome (FMS) including 
myotonic dystrophy type 2 (DM2); we try to answer the question whether and when one 
needs to look for other muscular disorders in patients with (suspected) FMS. In part II, the 
multisystem aspects of DM2 are discussed and recommendations are made on how to 
manage these symptoms. In addition, in order to recognize and diagnose this complex 
disorder more easily, we present a proposed flowchart on when to consider DM2. This 
flowchart needs further confirmation and validation. 
PART I 
Epidemiology of DM2 and other muscular disorders in fibromyalgia syndrome
FMS is a major healthy issue because of its high prevalence of 2% and impact on quality of 
life [1-4]. FMS can be diagnosed using the preliminary 2010 American College of Rheumatology 
(ACR) diagnostic criteria: one of those criteria is the absence of another disease that could 
cause the complaints [5]. It is however unclear which diagnoses should be excluded, although 
numerous blood tests have been recommended as routine screening [6]. 
The pain described by patients with DM2 shows some striking similarities to the pain 
experienced by patients with FMS (Table 8.1), and there is a high prevalence of associated 
symptoms including fatigue and gastrointestinal symptoms that can occur in both diseases [7,8]. 
We assessed the DM2 mutation in almost 400 patients with suspected FMS because of the 
clinical similarities (Chapter 2). Only one patient appeared to have DM2 and this was not 
considered as a relevant excess prevalence of DM2 in FMS. In 373 patients with suspected 
FMS, also creatine kinase (CK) and thyroid stimulating hormone (TSH) serum levels were 
tested in secondary care setting (Chapter 3). According to the European Federation of the 
Neurological Societies reference standard, only two patients had an abnormal serum CK and 
in both of them a repeated serum CK test was normal [15]. TSH was elevated in 13 patients 
and decreased in five patients, while only one patient had a somewhat lowered free thyroid 
hormone level. The final diagnosis was FMS (ICD-9 diagnosis classification) in all these 
patients according to their treating rheumatologist. In conclusion, routine testing of serum 
CK and TSH in 373 secondary care patients with suspected FMS did not lead to an alternative 
diagnosis. 
Although many muscular disorders present with muscle weakness, pain may also be 
present in a widespread distribution and resemble the pain reported in FMS. Several case 
reports described patients with a muscular disorder in who FMS was diagnosed formerly. 
Nam et al. described two patients with myotonia congenita who were previously diagnosed 
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with FMS [16]. Late onset Pompe disease was established in two sisters who were followed 
for years with the diagnosis of FMS [17]. Another case was formerly diagnosed with FMS and 
turned out to have hyperkalemic periodic paralysis [18]. In our study reported in Chapter 4, 
one patient with presumed FMS appeared to have limb girdle muscular dystrophy (LGMD). 
To our knowledge, only two other, much smaller studies, have examined the presence of a 
muscular disorder in a cohort of FMS patients in addition to the large study presented in this 
thesis. In two of 63 patients with initially diagnosed FMS, DM2 was established (sisters) and in 
93 patients with FMS a mutation in the sodium channel (SCN4A) gene (c.3466G.A p.A1156T) 
was examined, but absent in all [7,19].
Frequent complaints of patients with proximal weakness due to a muscular disorder are 
difficulty climbing stairs and standing up from a seated position. Also, a familial occurrence 
may be present, as well as exercise-related symptoms and other systemic features. However, 
in our study, respectively 32%, 38% and 50% of patients with suspected FMS had anamnestic 
difficulty in climbing stairs, standing from squat position and lifting 5 kilograms above their 
head (Chapter 2). Moreover, 55% of the patients with suspected FMS had at least one family 
member with similar complaints. A familial aggregation of FMS is a well-known phenomenon 
in the literature [20,21]. Consequently, questions focused on proximal muscle weakness 
and familial occurrence does not seem to differentiate between FMS and a (genetic) muscular 
disorder.
We conclude that certain rare muscular disorders including DM2 may mimic FMS. 
However, diagnosing a muscular disorder in patients with FMS seems to occur only 
sporadically. It is difficult to recognize these sporadic cases, especially when clear muscle 
weakness is absent and the disorder is unknown or not diagnosed in the family. We do not 
recommend standard testing of the DM2 mutation in patients with suspected FMS. We neither 
recommend the routine testing of CK and TSH in patients with suspected FMS in secondary 
care setting. However, it is warranted to electively test patients with signs and/or symptoms 
suggestive of DM2, another muscular disorder, or thyroid disease and appropriate diagnostic 
and therapeutic steps should follow accordingly. 
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Table 8.1 Clinical similarities and differences between DM2 and FMS 
Features  DM2 FMS
Muscles
   Pain
   Pain prevalence
   Pain severity: VAS (median)
   Muscle weakness
      Localization
   Myotonia
   Serum CK
   Central sensitization
Widespread fluctuating pain
65%
31
Usually present
Proximal muscles
Usually present
Normal to moderate increase
Perhaps, at least less 
pronounced than in FMS
Widespread fluctuating pain
100%
58
May be present
No specific pattern
Absent
Normal
Present
Eyes
   Early-onset cataract Common Absent
Heart
   Cardiac arrhythmias May be present Absent
Central nervous system
   Fatigue
   Sleep disturbances
Usually present
Bad sleep quality
Restless legs syndrome
Present
Bad sleep quality
Nonrestorative sleep
Gastrointestinal system
   Gastrointestinal symptoms Common Common
Other
   Mood disorder
   Headache
   Familial occurrence
Unknown
Unknown
Common
Common
Common
Common
Abbreviations: DM2, myotonic dystrophy type 2; FMS, fibromyalgia syndrome; VAS, visual analogue scale; CK, 
creatine kinase.
Findings described in this thesis (Chapter 2, 4 and 5) are in red [1,7-14]
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PART II 
Multisystem aspects of DM2
Prevalence of DM2
The exact prevalence of DM2 is unknown and seems to vary geographically with a high 
frequency in Germany and Finland, probably due to a founder effect [8,22,23]. The number of 
known Dutch patients with DM2 has grown from 45 patients in 2011 to 111 in 2016, which 
means almost a threefold increase in the number of diagnoses of DM2 (unpublished data). 
We genetically tested 398 patients with suspected fibromyalgia syndrome for DM2, 
one patient showed to have the DM2 mutation (Chapter 2). This was considered as not a 
relevant excess frequency (0.25%) of DM2 in patients with suspected FMS. Auvinen et al. 
reported a prevalence of 3% DM2 in 63 patients with FMS in Finland [7]. Perhaps these data 
reflect the overall prevalence of DM2 in both countries (i.e. much higher in Finland than 
in the Netherlands). Otherwise, the Finnish prevalence of DM2 in FMS might also be an 
overestimation, especially as these two patients appeared to be sisters. 
Pain
For many patients with neuromuscular disorders, chronic pain is a frequent and highly 
relevant problem, impairing quality of life [24-26]. The pathophysiology is, however, poorly 
understood and to date chronic pain continues to be a major clinical challenge that has not 
yet been fully studied; tailored treatment strategies are largely unknown [25].
In our comprehensive study of qualitative as well as quantitative aspects of pain, we 
confirmed the presence of pain as a frequent and important symptom in patients with DM2 
and its relevance with respect to quality of life (Chapter 4). The prevalence of pain in our 
study (65%) was comparable to the findings of Suokas et al. (lifetime prevalence of 76%) 
and Day et al. (56%); higher than reported by Moxley et al. (46%) and lower than reported by 
Peric et al. (86%) [10,11,27,28]. Furthermore, we demonstrated widespread hyperalgesia in DM2 
with measurement of pressure pain thresholds (PPT), indicative of a peripheral mechanism 
of pain. The extent of hyperalgesia is also suggestive of central sensitization, but this was not 
supported by the other results. Two previous studies have measured PPT in patients with 
DM2. Moshourab et al. also reported decreased PPT in 23 patients with DM2, whereas George 
et al. only reported a tendency toward local mechanical hyperalgesia in a small study of 13 
patients with DM2 [29,30]. 
Pain prevalence and severity was higher in patients with FMS compared to patients 
with DM2 in our study, and patients with FMS clearly showed signs of central sensitization 
(see Table 8.1 for the comparison between DM2 and FMS). 
In conclusion, pain is a frequent and important symptom in patients with DM2. Patients 
with DM2 show signs of widespread mechanical hyperalgesia, indicative of a peripheral 
mechanism of pain. Whether central sensitization plays a role as well needs further 
exploration. We recommend to pay attention to this disabling symptom and to put effort 
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in treating it symptomatically. Further research is necessary to find answers to the question 
whether central sensitization does play a role in the pathophysiology of pain in DM2, 
ultimately to be able to create a mechanism-based treatment.  
Gastrointestinal symptoms
In general, chronic constipation is associated with an impaired quality of life [31]. Furthermore, 
impairment in work productivity and activity has been described in patients with chronic 
constipation [32]
A high prevalence of gastrointestinal symptoms was found in our study, the most common 
were abdominal pain, constipation (both 62%) and dysphagia for solid food (41%) (Chapter 5, 
for dysphagia see also Chapter 6). The presence of constipation was confirmed by an elevated 
constipation score compared to healthy controls, and an increased colon transit time in 24% 
of patients with DM2. In a recent report regarding gastrointestinal manifestations in 180 
patients with DM2, 53% reported constipation, thereby confirming our results [33]. Seventy-
seven percent reported at least one gastrointestinal symptom. Next to constipation and 
dysphagia, acid reflux was common (46%) as well as gallbladder problems with a prevalence 
of cholecystectomy of 13% [33].
The pathophysiology of constipation in DM2 has not been explored in other studies. 
Proposed pathophysiological mechanisms of constipation in the myotonic dystrophies 
include dysfunction of the smooth muscles, myotonia, endocrine disturbances, and 
inflammation [33,34]. Possibly, reduced mobility plays a role as well. Our finding of an increased 
colon transit time supports the hypothesis of a motility disorder due to dysfunction of the 
smooth muscles. 
In conclusion, gastrointestinal symptoms are common in DM2, especially constipation 
and abdominal pain. The pathophysiology remains unclear, however, it seems likely 
that smooth muscle dysfunction plays a role. We recommend to regularly inquire about 
gastrointestinal symptoms so adequate treatment can be provided if necessary. Moreover, 
caution should be taken in prescribing opiates for pain because of the negative side effects 
on gastrointestinal motility.  
Dysphagia
Dysphagia is a prevalent symptom in many different neuromuscular disorders [35]. 
Embarrassment about symptoms such as choking, coughing, or spluttering while eating 
and long meal times can have a negative impact on daily functions and social participation 
in patients with swallowing difficulties [36,37]. Severe dysphagia may lead to life-threatening 
medical complications such as extreme weight loss or aspiration pneumonia [38,39]. 
Difficulty in swallowing of solid food was reported by 41% of the patients that 
participated in our study about gastrointestinal dysfunction (Chapter 5). Additional testing 
in ten of them, by an experienced speech therapist and fiberoptic endoscopic evaluation of 
swallowing (FEES), confirmed the presence of dysphagia in all of them (Chapter 6). Dysphagia 
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was generally mild and did not lead to aspiration pneumoniae or short weight in our 
population. A similar number of patients with DM2 (29% of 180 patients) reported difficulty 
with swallowing in a recent article about patient-reported gastrointestinal manifestations in 
the myotonic dystrophies [33]. To our knowledge, there are no other reports about dysphagia 
in DM2 except a few case reports [40-42]. Manometry showed oesophageal spasms in one case 
of DM2 as the presumed cause of dysphagia, while Day et al. described three patients with 
dysphagia, who also had suffered from aspiration [40,41].
The pathophysiology of dysphagia in DM2 remains unclear. We found minimal signs of 
weakness in the tongue, lips and jaws in some of our patients, and no myotonia in the tongue 
or masseter muscles. In DM1, dysphagia is generally more severe and probably primarily due 
to facial muscle weakness [43,44]. The role of myotonia in the pathophysiology of dysphagia 
in DM1 is unclear; dysphagia may be aggravated by the cognitive impairment with poor 
symptom awareness in patients with DM1 [44,45]. There is a correlation between dysphagia 
and dysarthria in patients with DM1 [44]. Since the oral phase of swallowing is mostly affected 
in DM1 due to facial muscle weakness, they have more difficulty with solid bolus than with 
liquids (in contrast to patients with amyotrophic lateral sclerosis) [43,44]. 
Perhaps the same mechanisms, muscle weakness and myotonia, might play a role 
in dysphagia in DM2. However, this needs confirmation with further research, preferably 
with swallowing assessment by a speech therapist and otorhinolaryngologist in a larger 
population of patients with DM2, both with and without complaints of dysphagia.
In conclusion, dysphagia in DM2 is common but generally mild. More research is 
needed to explore its pathophysiology. We recommend to regularly ask patients with DM2 
about swallowing difficulties; when dysphagia is reported, the patients can be referred to an 
experienced speech therapist for analysis of the severity and assistance. 
Hearing impairment
Numerous data show that patients with hearing impairment have a significantly poorer 
health-related quality of life compared to healthy controls [46,47]. Rehabilitation with hearing 
aids can improve subjective hearing and health-related quality of life [46].
Hearing impairment was self-reported by 75% of our study population (Chapter 7) and 
results of pure tone audiometry clearly established the presence of hearing impairment in 
DM2. Hearing impairment was mild in 39%, moderate in 21% and severe in 2% of patients 
with DM2. Auditory characteristics have never been systematically examined before in 
DM2. Our results confirm and extend multiple case reports and case series in which hearing 
impairment in DM2 is reported [40-42,48-52]. Meola et al. reported sensorineural deafness in 40% 
of 60 patients with DM2 [48]. Also, six out of 22 patients (27%) with DM2 were reported with 
hearing impairment before the age of 60 years [41].
The origin of the sensorineural hearing impairment is probably located in the 
cochlea, based on the absence of an air-bone gap in PTA, concordant speech audiometry 
to PTA, normal tympanometry, and normal BAEPs in our report. The results are suggestive 
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of an early presbycusis. In DM1, similar findings have been described: a sensorineural 
hearing impairment, resembling early presbycusis [53-57]. Many symptoms of the myotonic 
dystrophies can be considered as a result of premature aging, such as muscle weakness, 
cataract, baldness, and cognitive decline [58]. The phenomenon of early presbycusis fits well 
in this hypothesis. Also of interest is the finding of a locus for hearing impairment (DFNA18) 
immediately adjacent to the DM2 locus [59]. Perhaps the repeat expansion of the CNBP 
gene influences this locus. Next to the DM1 locus lies a locus for hearing impairment as 
well (DFNA4) [60].
In conclusion, sensorineural hearing impairment is a frequent symptom in patients 
with DM2, with the phenotype of an early presbycusis. The origin is located in the cochlea. 
We recommend to inform patients about this symptom and to readily perform audiometry 
when reported, so hearing aids can be prescribed when indicated.
Figure 8.1 Multisystem involvement in DM2 including new symptoms described in this thesis   
Cataract
Cardiac arrythmias
Cardiomyopathy
Weakness
Myotonia
Pain Autoimmune diseases
None or mild cognitive
dysfunction
White matter involvement
Thyroid dysfunction
Diabetes mellitus 
type 2
Hearing loss
Dysphagia
Abdominal pain
Constipation
Male hypogonadism
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Remarks on the different clinical pictures of DM2 and DM1
Although both DM2 and DM1 are autosomal dominant inherited disorders with muscle 
weakness, myotonia, early-onset cataract and multisystem involvement, during our 
observations we learned that the differences seem more apparent than the similarities 
between both disorders. The average time to reach correct diagnosis was reported to be 14-
16 years in DM2, twice as long as in DM1 [61].  
In DM1 there is a clear correlation between the length of the repeat expansion and the 
phenotype. Also, there is a congenital form of DM1 and anticipation (more severe disease 
at younger age and longer repeat length in each consecutive generation), whereas DM2 
generally lacks these features. 
In an adult-onset patient with DM1 a distinct phenotype can be seen, consisting of a 
more or less severe presence of distal and facial muscle weakness, marked myotonia, frontal 
baldness, cognitive impairment with impaired disease awareness in addition to signs of 
multisystem involvement which may include early-onset cataract, male hypogonadism, 
thyroid dysfunction, gastrointestinal symptoms, cardiac arrhythmias and excessive daytime 
sleepiness [62-64]. Due to cardiac involvement and dysphagia with the risk of aspiration 
pneumonia, lifespan is generally reduced [38].  
In DM2, there is no such ‘typical patient’. The phenotype in DM2 is highly variable, 
ranging from paucisymptomatic elderly patients with only an elevated serum CK, to subjects 
who suffer mainly from myalgia, to wheelchair bound patients due to severe proximal muscle 
weakness, with severe hearing impairment and pacemaker implantation. Although some 
patients with DM2 may die prematurely from cardiac arrhythmias, in general, life expectancy 
is not reduced in DM2. 
DM2: a diagnostic odyssey
In summary, DM2 is still difficult to recognize and diagnose due to its rarity, unfamiliarity by 
clinicians and its strikingly heterogeneous phenotype. Based on our clinical and scientific 
experience, we have made a proposal with a flowchart on when to consider DM2 (Figure 8.2). 
In Table 8.2 the most common multisystem features are presented, including their prevalence 
based on this thesis as well as the largest reports about DM2 to date [11-13,61]. The three most 
common initial symptoms of DM2 as reported in the literature are proximal muscle weakness, 
myotonia and pain; these were taken as baseline features in the proposed flowchart [11-13,61]. 
Evidently, this proposed flowchart needs (international) confirmation and validation. 
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Table 8.2 Prevalence of multisystem features of DM2
DM2 feature Prevalence
Muscle weakness
Clinical myotonia
Electrophysiological myotonia
Early-onset cataract
Pain
Elevated serum CK
Hearing impairment
Constipation
Dysphagia
Cardiac arrhythmias 
Diabetes mellitus type 2
Thyroid dysfunction 
Male hypogonadism
Autoimmune disorders
80%
41-75%
80-90%
50-75%
46-86%
48-78%
60%
39-62%
29-41%
8-22%
17-30%
32%
20%
21%
Abbreviations: DM2, myotonic dystrophy type 2; CK, creatine kinase.
[10-14,27,28,30,33,61,66,67 and this thesis]
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CONCLUSIONS
• There is no relevant excess frequency of DM2 in patients with suspected FMS.
• Routine genetic testing for DM2 is not recommended in patients with suspected FMS.
• Routine screening of CK and TSH is not recommended in patients with suspected FMS 
in secondary care setting as abnormal values of both are rare and do not result in an 
alternative diagnosis.
• Pain is a frequent and important symptom in patients with DM2, associated with a 
poorer quality of life.
• Peripheral mechanisms seem to play a role in the pathophysiology of pain in patients 
with DM2.
• The role of central sensitization in pain in patients with DM2 remains unclear and needs 
more research.
• Gastrointestinal dysfunction is frequent and disabling in patients with DM2, and includes 
dysphagia, abdominal pain, and constipation.
• Dysphagia is present in patients with DM2, generally mild and not leading to aspiration 
pneumonia or short weight.
• Sensorineural hearing impairment resembling early presbycusis is a frequent sign in 
patients with DM2.
• DM2 remains a challenging diagnosis due to its enormous broad range of possible 
symptoms and signs and its highly heterogeneous phenotype.
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FUTURE PERSPECTIVES
Reducing the diagnostic delay
This thesis adds various new clinical aspects to the phenotype of DM2 and thereby extends its 
wide variety of possible signs and symptoms. Diagnosing this disease remains challenging, 
and future research should focus on the question of how to shorten the diagnostic delay. We 
took a first step in diagnostic improvement with the proposed flowchart as shown in Figure 8.2, 
based on our expert opinion. Discussing this unvalidated flowchart with international DM2 
experts at the European Neuromuscular Centre (ENMC) workshop would be a good next step. 
As shown in Figure 8.2, the three most common features of DM2 are proximal muscle 
weakness, myotonia and pain [11-13,61]. Pain is a common symptom in the general population; 
proximal muscle weakness is frequently present in other muscular disorders. Myotonia, 
however, is a cardinal feature of the nondystrophic and dystrophic myotonias, but is only 
rarely present in other muscular disorders [67]. The prevalence of myotonic discharges 
on electromyography (EMG) is between 80 and 90% in DM2 [11-13,68]. It would be of interest 
to determine the exact features and localisation of both clinical and electrophysiological 
myotonia in DM2, which could lead to a good clinical test with a presumed high specificity 
for the DM2 diagnosis. 
It would also be of interest to explore the diagnostic road that patients with DM2 have 
followed before DM2 was diagnosed. Perhaps certain diagnoses were considered quite 
frequently (such as FMS) before the definite diagnosis was reached.  
Improving symptomatic management
Another important direction for future research is to improve symptomatic management. 
Pain is an important symptom in patients with DM2, associated with a poorer quality of life 
as shown in Chapter 4 of this thesis. Tailored treatment strategies are however unknown. 
An elegant and suitable way of assessing the effect of medication in patients with DM2 is 
an n-of-1 trial. While randomized controlled trials are effective in defining and predicting 
a response at population level, n-of-1 trials are helpful in defining individual responses to 
treatment and are particularly useful in chronic rare diseases such as DM2 (with low patient 
numbers and high clinical heterogeneity). N-of-1 trials or single patient trials are double-
blind, randomized, crossover comparisons, comparing a drug with placebo (or another drug) 
within a single patient [69-71]. Series of n-of-1 trials can also be meta-analyzed to measure the 
results at population level [72]. 
In general, mexiletine is the first drug of choice for treating myotonia in DM1 and 
nondystrophic myotonias; however the effect of mexiletine on myotonia in DM2 has not 
been assessed [73,74]. Moreover, mexiletine has been shown to be effective in reducing pain in 
chronic pain conditions such as a painful diabetic neuropathy [75,76]. It would be interesting 
to measure the effect of mexiletine both on myotonia and pain in patients with DM2 in an 
aggregated n-of-1 trial. Primary outcome measurements may well be the severity score of 
stiffness and pain reported via the interactive voice response diary, a method described by 
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Statland et al. and Stunnenberg et al. [71,74]. Secondary outcome measurements may include 
quality of life by the SF-36 healthy survey; myotonia bedside tests and needle EMG; and 
measurement of pressure pain thresholds by pressure algometry according to the method 
described in Chapter 4 of this thesis. A pilot study in a single patient (individual n-of-1 trial) 
will be a good start. 
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Abbreviations: ACR, American College of Rheumatology; BAEP, brainstem auditory evoked potential; CK, creatine 
kinase; CNBP, cellular nucleic acid binding protein; DM1, myotonic dystrophy type 1; DM2, myotonic dystrophy 
type 2; DOSS, Dysphagia Outcome and Severity Score; FEES, fiberoptic endoscopic evaluation of swallowing; FMS, 
fibromyalgia syndrome; ICD-9, international classification of disease, version 9; PPT, pressure pain threshold; PTA, 
pure tone audiometry; QST, quantitative sensory testing; TSH, thyroid stimulating hormone.
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ENGLISH SUMMARY
Myotonic dystrophy type 2 (DM2) is a dominantly inherited multisystem disorder. The clinical 
features were described in 1994 for the first time. In 2001, an unstable CCTG expansion in 
intron 1 of the CNBP gene, mapped to chromosome 3q21.3, was discovered as the cause of 
DM2. The symptoms and signs of DM2 typically present in adult life. Predominant muscular 
features are proximal muscle weakness, pain and myotonia. Many other systems and organs 
may be involved as well, e.g. early-onset cataract, endocrine disturbances including thyroid 
dysfunction and diabetes mellitus type 2, cognitive and sleep disturbances and cardiac 
involvement might be present. 
In the introduction of this thesis (Chapter 1), the clinical features of DM2 are described and 
compared to myotonic dystrophy type 1 (DM1). The DM2 phenotype is highly variable, ranging 
from paucisymptomatic elderly patients to younger patients who are wheelchair bound due 
to proximal muscle weakness. Pain is a predominant symptom which often is, next to fatigue 
and stiffness, one of the atypical symptoms at onset. The clinical features may show many 
similarities to fibromyalgia syndrome (FMS), a common disorder with widespread pain. The 
often nonspecific onset symptoms, together with the rarity of the disorder and the extensive 
interindividual variability in clinical features makes DM2 a difficult disorder to recognize. A 
mean diagnostic delay of 14-16 years has been described (time between onset of symptoms 
and diagnosis). Although diagnosing DM2 gives patients clarity about the cause of their 
symptoms, there is no curative treatment. However, many aspects of this multisystem 
disorder can be treated symptomatically in collaboration with rehabilitation specialists, 
ophthalmologists and cardiologists. Cataract may need conventional surgical treatment, 
while regular cardiologic examination is recommended and implantation of a pacemaker 
may be indicated in case of rhythm abnormalities. Finally, patients with DM2 and their 
relatives merit genetic counselling.
The aim of this thesis is to broaden our knowledge about epidemiological aspects 
and the phenotype of DM2; not only to get a better understanding of its complicated 
pathophysiology, but also to be able to shorten the diagnostic delay and to improve 
symptomatic management.
PART I 
Epidemiology of DM2 and other muscular disorders in fibromyalgia syndrome
In Chapter 2, the results of an epidemiologic study are described, in which 398 patients with 
suspected FMS were genetically tested for DM2. The two main reasons to perform this study 
were the striking similarities in pain characteristics experienced by patients with DM2 and 
FMS, and the presumed underreporting of DM2 in the Netherlands. In advance, a prevalence 
of 2% DM2 in this population was considered a relevant excess frequency. In 96% of the study 
population, FMS was the final diagnosis according to the ICD-9 classification. Ninety-two 
percent of the study population met the preliminary 2010 American College of Rheumatology 
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(ACR) diagnostic criteria for FMS. DM2 was established in only one of the 398 patients (0.25%, 
95% CI 0.04–1.4%), thus disapproving our hypothesis of a relevant prevalence of 2%. We 
propose that in patients with suspected FMS genetic testing for DM2 should not routinely be 
performed. 
Next, we determined the prevalence of abnormal serum creatine kinase (CK) and thyroid 
stimulating hormone (TSH) in 373 patients with suspected FMS in secondary care setting, 
with a previously unknown myopathy or thyroid disease (Chapter 3). Of these patients, 7.5% 
(95% CI: 5.2-10.6%) had an abnormal CK according to the local reference values. Applying 
the European Federation of the Neurological Societies guideline, only two patients had an 
elevated CK (0.5% (95% CI: 0.2-1.9%)). In both patients, a subsequent CK was normal. In none 
of these patients hyperCKemia-related myopathy was diagnosed; the final diagnosis was 
FMS in 89% of the patients. Of the total number of patients, 3.5% (95% CI: 2.1-5.9%) had an 
elevated TSH and 1.4% (95% CI: 0.6-3.1%) a lowered TSH. Only one patient had a somewhat 
lowered free thyroid hormone level. The final diagnosis was FMS in all these patients. In 
conclusion, abnormal CK and TSH values are rare in patients with suspected FMS and do 
not result in an alternative diagnosis. We recommend that in patients with suspected FMS 
referred to secondary care routine testing of serum CK and TSH should not be performed. 
PART II 
Multisystem aspects of DM2
Pain is one of the most important symptoms for patients with DM2. In an explorative study, 
described in Chapter 4, we assessed qualitative and quantitative aspects of pain in DM2. Next 
to the completion of four questionnaires, quantitative sensory testing (QST) was performed 
to establish mechanical and electrical pain thresholds. The results were compared to two 
age- and sex-matched control groups: one group of patients with FMS and one group with 
healthy controls. Thirty-four patients with genetically confirmed DM2 (71% female, mean age 
54 years), 28 patients with FMS and 33 healthy controls were included, both matched for age 
and sex. Pain prevalence was 65% in DM2, 100% in FMS (P < 0.001) and 15% in healthy controls 
(P < 0.001). A significant correlation was found between the severity of pain and several 
aspects of health-related quality of life in DM2. The mean of the pressure pain thresholds was 
lower in DM2 than in healthy controls (P = 0.016), with the largest differences in the rectus 
femoris, trapezius and thenar muscles, consistent with hyperalgesia. No differences were 
found in electric pain thresholds between DM2 and healthy controls. Mechanical and electric 
pain thresholds were significantly higher in DM2 than in FMS.
The results confirm that pain is a frequent and important symptom in patients with 
DM2 and an association between pain and a poorer quality of life was found. Peripheral 
mechanisms seem to play a role in the pathophysiology of pain in DM2, given the finding 
of hyperalgesia. Central sensitization is the amplification of neural signalling within the 
central nervous system, expressed as spreading or generalized hyperalgesia. The extent of 
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the hyperalgesia we found is suggestive of central sensitization, but the other results do not 
support this finding. This study opens new avenues for further research and expectantly 
novel treatment strategies, both for DM2 as well as other muscular disorders. 
Chapter 5 covers the results of a cross-sectional study exploring gastrointestinal dysfunction in 
patients with DM2. Twenty-nine patients with DM2 filled out two standardized questionnaires 
about gastrointestinal symptoms. The results were compared to the answers of 29 patients 
with adult-onset DM1 and to 87 healthy controls, both age- and sex-matched. Furthermore, 
radiological measurement of colon transit time was established in 18 patients with DM2. 
Dysphagia for liquids (38%) and solid food (41%), abdominal pain (62%), and constipation 
(62%) were all significantly more common among patients with DM2 than among healthy 
controls, comparable to their occurrence in DM1. Colon transit time was increased in 24% 
of the patients with DM2. The results show that gastrointestinal symptoms are highly 
prevalent in patients with DM2. Gastrointestinal dysfunction may be present in any part of 
the gastrointestinal tract.
Twelve patients with DM2 who participated in the previously mentioned study about 
gastrointestinal symptoms reported to have difficulty in swallowing for solid food. Swallowing 
function was examined in ten of them by a speech therapist experienced in neuromuscular 
disorders. In addition, fiberoptic endoscopic evaluation of swallowing (FEES) was performed 
in eight of the twelve patients by an otorhinolaryngologist. The presence of dysphagia was 
confirmed, clinically in 100% and by FEES in 88%, as described in Chapter 6. A correlation was 
found between the severity of dysphagia measured by the Dysphagia Outcome and Severity 
Score (DOSS) and age. None of the patients were short weight, had previously suffered 
from aspiration pneumonia or had signs of aspiration with FEES. In conclusion, the results 
demonstrate that dysphagia is present in patients with DM2 and is more severe in older 
patients. However, dysphagia is generally mild and does not lead to aspiration pneumonia 
or short weight.  
The results of a prospective international study about the presence of hearing impairment 
are described in Chapter 7. Fifty-six patients with DM2 (31 Dutch and 25 French patients) 
were included and underwent a structured interview about hearing symptoms, standardized 
otologic examination, pure tone audiometry (PTA), speech audiometry, tympanometry, 
acoustic middle ear muscle reflexes, and brainstem auditory evoked potentials (BAEP). The 
median hearing threshold of the DM2 cohort was higher at all measured frequencies with PTA, 
compared to the 50th percentile of normal (P < 0.001). Hearing impairment was mild in 39%, 
moderate in 21%, and severe in 2% of patients with DM2. The absence of an air–bone gap with 
PTA, concordant results of speech audiometry with PTA, and normal findings of BAEP suggest 
that the sensorineural hearing impairment is located in the cochlea. A significant correlation 
was found between hearing impairment and age, even when corrected for (physiologically 
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normal) presbycusis. In conclusion, cochlear sensorineural hearing impairment is a frequent 
sign in patients with DM2, suggestive of an early presbycusis. Therefore, we recommend to 
inform patients about hearing impairment. In order to propose early hearing rehabilitation 
with hearing aids when indicated, audiometry should readily be performed when hearing 
impairment is suspected.
Most of our research questions were formulated on the basis of our experiences in daily 
clinical practice. In the general discussion (Chapter 8) we compare the results described in 
this thesis to the most recent literature and try to translate our findings back into daily clinical 
practice. 
Part I covers the differential diagnosis of FMS including DM2. We conclude that certain 
rare muscular disorders including DM2 may mimic FMS. However, diagnosing a muscular 
disorder in patients with FMS seems to occur only sporadically. We do not recommend 
testing the DM2 mutation standard in patients with suspected FMS. We neither recommend 
the routine testing of serum CK and TSH in patients with suspected FMS in secondary 
care setting. Certainly, elective testing should still be performed in patients with features 
suggestive of DM2, another muscular disorder or thyroid disease. 
In part II the multisystem aspects of DM2 are discussed and compared to recent 
findings in the literature. The DM2 phenotype is extended with the common occurence of 
gastrointestinal symptoms and hearing impairment as well as the generally mild presence of 
dysphagia based on our findings. We propose a flowchart of aid on when to consider DM2, 
which needs further confirmation and validation. Finally, we make several proposals for 
future investigations, aimed at a further reduction of the diagnostic delay and improvement 
of symptomatic management in patients with DM2. 
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DUTCH SUMMARY - NEDERLANDSE SAMENVATTING
Inleiding
Myotone dystrofie type 2 (DM2) is een autosomaal dominant overervende 
multisysteemaandoening. De klinische kenmerken werden voor het eerst in 1994 beschreven 
door Ricker et al. en Thornton et al. In 2001 werd een onstabiele CCTG-expansie in intron 1 
van het CNBP-gen ontdekt op chromosoom 3q21.3 als de oorzaak van DM2. De symptomen 
ontstaan meestal op volwassen leeftijd, gemiddeld tussen de derde en vierde decade. 
Belangrijke neuromusculaire kenmerken zijn proximale spierzwakte, pijn en myotonie. 
Daarnaast is er vaak sprake van betrokkenheid van andere organen en systemen, zoals 
de ogen (cataract op jonge leeftijd), schildklier (voornamelijk hypothyreoïdie, soms 
hyperthyreoïdie), pancreas (diabetes mellitus type 2), hart (hartritmestoornissen) en de 
hersenen (milde cognitieve stoornissen). 
In de inleiding van dit proefschrift (Hoofdstuk 1) worden de klinische kenmerken van 
DM2 beschreven en vergeleken met myotone dystrofie type 1 (DM1). Het DM2 fenotype is 
zeer variabel, variërend van oudere patiënten met nauwelijks symptomen tot jongere 
patiënten die rolstoel gebonden zijn vanwege proximale spierzwakte, met veel pijn en 
soms hartritmestoornissen. Initiële symptomen zijn vaak aspecifieke klachten zoals pijn, 
stijfheid en vermoeidheid. Er kunnen sterke overeenkomsten zijn met de klachten van 
patiënten met fibromyalgie syndroom (FMS). FMS is een veel voorkomende aandoening met 
gegeneraliseerde pijn, beschreven in Hoofdstuk 1. DM2 is moeilijk te herkennen, door de 
vaak aspecifieke initiële symptomen, de lage prevalentie en de uitgesproken heterogeniteit 
van het ziektebeeld. Gemiddeld duurt het 14-16 jaar tussen het eerste symptoom en het 
stellen van de diagnose DM2. Vermoedelijk is er sprake van onderrapportage van DM2 in 
Nederland. Hoewel er geen curatieve behandeling bestaat, geeft het diagnosticeren van 
DM2 uitsluitsel over de oorzaak van de symptomen van patiënten. Bovendien kunnen veel 
aspecten van deze multisysteemziekte symptomatisch worden behandeld in samenwerking 
met revalidatieartsen, oogartsen en cardiologen. Vaak is een chirurgische behandeling 
geïndiceerd voor het cataract. Regelmatig cardiologisch onderzoek wordt aanbevolen, en 
implantatie van een pacemaker is soms geïndiceerd indien er hartritmestoornissen zijn. 
Bovendien is genetische counseling van belang voor patiënten met DM2 en hun familieleden.
Het doel van dit proefschrift is om de kennis over de epidemiologische aspecten 
en het fenotype van DM2 te vergroten; niet alleen om een beter begrip te krijgen van de 
gecompliceerde pathofysiologie van deze genetische aandoening, maar ook om het 
diagnostisch traject te verkorten en de symptomatische behandeling van de verscheidenheid 
aan klachten te verbeteren.
DEEL I
Epidemiologie van DM2 en andere spierziekten bij verdenking FMS
In Hoofdstuk 2 worden de resultaten van een epidemiologisch onderzoek beschreven, 
waarin 398 patiënten met verdenking op FMS genetisch werden getest op DM2. Dit onderzoek 
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werd enerzijds verricht vanwege de vermoedelijke onderrapportage van DM2 in Nederland, 
en anderzijds vanwege de opvallende overeenkomsten in pijn tussen patiënten met DM2 
en FMS. Van tevoren werd een prevalentie van 2% patiënten met DM2 als een relevante 
verhoogde prevalentie beschouwd in deze populatie. 
FMS werd in 96% van de studiepopulatie gediagnosticeerd volgens de ICD-9 classificering. 
Tweeënnegentig procent van de studiepopulatie voldeed aan diagnostische criteria voor 
FMS, zoals opgesteld door het Amerikaanse College van Reumatologie in 2010. DM2 werd 
vastgesteld bij slechts één van de 398 patiënten (0,25%; 95% betrouwbaarheidsinterval 
0,04-1,4%), waarmee onze hypothese van een relevant verhoogde prevalentie van DM2 
bij patiënten verdacht van FMS werd verworpen. Dit resultaat impliceert dat genetisch 
onderzoek naar DM2 niet routinematig dient plaats te vinden bij patiënten met verdenking 
op FMS. 
Het serum creatinekinase (CK) en thyroïdstimulerend hormoon (TSH) werd, in de tweede 
lijn, bij 373 patiënten met verdenking op FMS bepaald met een voorheen onbekende 
myopathie of schildklieraandoening (Hoofdstuk 3). Van deze patiënten had 7,5% (95% 
betrouwbaarheidsinterval 5.2 – 10.6%) een verhoogd CK volgens de lokale referentiewaarden. 
Volgens de normaalwaarden van de richtlijn van de Europese Federatie van Neurologische 
Genootschappen (EFNS) hadden slechts twee patiënten een verhoogd CK (0,5% (95% 
betrouwbaarheidsinterval 0.2 - 1.9%)). Bij beide patiënten was een opeenvolgend serum 
CK normaal. Bij geen van deze patiënten werd een hyperCKemie gerelateerde myopathie 
gediagnosticeerd. De definitieve diagnose was FMS bij 89% van de patiënten volgens de ICD-
9-classificering. Van het totale aantal patiënten had 3,5% (95% betrouwbaarheidsinterval 
2.1 – 5.9%) een verhoogde TSH en 1,4% (95% betrouwbaarheidsinterval 0.6 - 3.1%) een 
verlaagde TSH. Slechts één patiënt had een licht verlaagd vrij schildklierhormoonniveau. De 
uiteindelijke diagnose was FMS bij al deze patiënten. Concluderend zijn abnormale CK- en 
TSH-waarden zeldzaam bij patiënten met verdenking op FMS en ze resulteren niet in een 
alternatieve diagnose. We adviseren dan ook niet om routinematig het CK en TSH te bepalen 
bij patiënten die verdacht worden van FMS in de tweede lijn.
 
DEEL II 
Multisysteemaspecten van DM2
Pijn is een van de belangrijkste symptomen van patiënten met DM2. In een observationele 
studie, beschreven in Hoofdstuk 4, hebben we de kwalitatieve en kwantitatieve aspecten van 
pijn bij patiënten met DM2 onderzocht. Er werden vier vragenlijsten ingevuld, en daarnaast 
werd een kwantitatieve sensorische test (QST) uitgevoerd om mechanische en elektrische 
pijndrempels te meten. De resultaten werden vergeleken met twee controlegroepen: 
één groep patiënten met FMS en één groep met gezonde controles, corresponderend in 
leeftijd en geslacht met de DM2 groep. Vierendertig patiënten met genetisch bevestigd DM2 
(71% vrouw, gemiddelde leeftijd 54 jaar), 28 patiënten met FMS en 33 gezonde controles 
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werden geïncludeerd. Pijnprevalentie was 65% in DM2, 100% in FMS (P < 0.001) en 15% in 
gezonde controles (P < 0.001). Er was een significante correlatie tussen pijn en verscheidene 
aspecten van kwaliteit van leven. Het gemiddelde van de mechanische pijndrempels was 
lager in DM2 dan in gezonde controles (P = 0.016), met de grootste verschillen in de rectus 
femoris, trapezius en thenar spieren, passend bij hyperalgesie. Mechanische en elektrische 
pijndrempels waren significant hoger in DM2 dan in FMS, terwijl er geen verschillen werden 
gevonden in elektrische pijndrempels tussen DM2 en gezonde controles. Deze resultaten 
bevestigen dat pijn een frequent en belangrijk symptoom is bij patiënten met DM2, met een 
associatie tussen pijn en een slechtere kwaliteit van leven. Perifere pijnmechanismen lijken 
een rol te spelen in de pathofysiologie van pijn in DM2. De gegeneraliseerde hyperalgesie 
duidt op centrale sensitisatie, maar deze bevinding werd niet ondersteund door de andere 
resultaten. Deze resultaten zijn een eerste stap in de ontrafeling van de oorzaak van pijn in 
DM2, verder onderzoek – in DM2 maar ook in andere spierziekten – kan wellicht leiden tot 
nieuwe behandelstrategieën. 
Hoofdstuk 5 behandelt de resultaten van een cross-sectionele studie naar gastro-
intestinale symptomen bij patiënten met DM2. Negenentwintig patiënten met DM2 vulden 
2 gestandaardiseerde vragenlijsten in over gastro-intestinale klachten. De resultaten 
werden vergeleken met de antwoorden van 29 volwassen patiënten met DM1 en met 87 
gezonde controles, gelijk in leeftijd en geslacht. Bovendien werd bij 18 patiënten met DM2 
de darmpassage tijd gemeten met een buikoverzichtsfoto. Dysfagie voor vloeistoffen (38%) 
en vast voedsel (41%), buikpijn (62%) en obstipatie (62%) werden allemaal significant vaker 
gerapporteerd door patiënten met DM2 dan door gezonde controles; de frequenties waren 
vergelijkbaar tussen DM2 en DM1. De passagetijd van het colon was verlengd bij 24% van de 
patiënten met DM2. De resultaten tonen aan dat gastro-intestinale symptomen zeer vaak 
voorkomen bij patiënten met DM2, met name buikpijn en obstipatie. 
Twaalf patiënten met DM2 die deelnamen aan het eerder genoemde onderzoek naar gastro-
intestinale symptomen rapporteerden dat ze moeite hadden met het slikken van vast 
voedsel. De slikfunctie werd in tien van hen onderzocht door een logopedist die ervaring 
had met neuromusculaire aandoeningen. Daarnaast werd ‘fiberoptische endoscopische 
evaluatie van slikken’ (FEES) uitgevoerd bij acht van de twaalf patiënten door een KNO-arts. 
De aanwezigheid van dysfagie werd in 100% van de patiënten klinisch bevestigd, met FEES 
werd er in 88% afwijkingen gevonden (Hoofdstuk 6). Er werd een correlatie gevonden tussen 
de ernst van dysfagie gemeten met de ‘Dysphagia Outcome and Severity Score’ (DOSS) en 
de leeftijd. Ondergewicht, een doorgemaakte aspiratiepneumonie of tekenen van aspiratie 
met FEES waren allen afwezig. Concluderend bevestigen de resultaten de aanwezigheid van 
dysfagie bij patiënten met DM2. Dysfagie is echter over het algemeen mild en leidt niet tot 
aspiratiepneumonie of ondergewicht.
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De resultaten van een prospectief internationaal onderzoek naar de aanwezigheid van 
slechthorendheid zijn beschreven in Hoofdstuk 7. Zesenvijftig patiënten met DM2 (31 
Nederlandse en 25 Franse patiënten) werden prospectief geïncludeerd en ondergingen een 
gestructureerd interview over gehoorsymptomen, gestandaardiseerd otologisch onderzoek, 
toonaudiometrie (PTA), spraakaudiometrie, tympanometrie, meting van stapediusreflexen 
en ‘brainstem auditieve evoked potentials’ (BAEP). De mediane gehoordrempel van het DM2 
cohort was hoger in alle gemeten frequenties met toonaudiometrie, vergeleken met het 50e 
percentiel van normaal (P < 0.001). Gehoorverlies was mild bij 39%, matig bij 21% en ernstig 
bij 2% van de patiënten met DM2. De gelijke uitkomsten van lucht- en botgeleiding met 
PTA, overeenkomstige resultaten van spraakaudiometrie met PTA, en normale bevindingen 
van BAEP suggereren dat de oorzaak van het perceptief gehoorverlies zich in de cochlea 
bevindt. Een significante correlatie werd gevonden tussen slechthorendheid en leeftijd, 
zelfs met correctie voor (fysiologisch normale) presbyacusis. Concluderend is cochleair 
perceptief gehoorverlies een veel voorkomend symptoom bij patiënten met DM2, gelijkend 
op een vroeg beginnende presbyacusis. We adviseren dan ook om regelmatig te vragen naar 
gehoorverlies en om laagdrempelig te verwijzen voor toonaudiometrie, zodat hoortoestellen 
tijdig aangemeten kunnen worden indien geïndiceerd. 
In Hoofdstuk 8 worden de resultaten zoals beschreven in dit proefschrift bediscussieerd, 
en vergeleken met de meest recente literatuur. De uitkomsten worden terug vertaald naar 
de dagelijkse praktijk, en er worden waar mogelijk handvatten en adviezen gegeven. In het 
eerste deel wordt ingegaan op de differentiaaldiagnose van FMS, met in het bijzonder DM2 
en andere spierziektes. Het lijkt er op dat het slechts sporadisch voorkomt dat patiënten 
foutief worden gediagnosticeerd met FMS terwijl ze een spierziekte blijken te hebben. Het 
stelselmatig testen van de DM2 mutatie bij patiënten die verdacht worden van fibromyalgie 
syndroom wordt niet geadviseerd. Ook het routinematig testen van het CK en TSH bij 
patiënten met verdenking fibromyalgie syndroom in de tweede lijn wordt niet geadviseerd. 
In deel twee wordt stilgestaan bij de multisysteemaspecten van DM2 en de complexiteit 
van de diagnose. Er wordt gesteld dat ondanks de overeenkomsten met DM1, zoals de 
autosomaal dominante overerving, spierzwakte, myotonie en multisysteembetrokkenheid, 
DM2 vooral een ander en minder herkenbaar fenotype kent. Er wordt een richtsnoer 
voorgesteld met een flowdiagram die de clinicus kan ondersteunen bij het afwegen van de 
diagnose DM2. Dit richtsnoer behoeft zeker nog bevestiging en validatie. Tot slot worden 
er suggesties gedaan voor toekomstig onderzoek, enerzijds met als doel een nog betere 
herkenning van DM2 en daarmee een verkorting van het diagnostisch traject; en anderzijds 
gericht op verbetering van symptomatische behandeling van patiënten met DM2. 
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CONCLUSIES
• Er is geen relevant verhoogde prevalentie van DM2 bij patiënten met verdenking op FMS.
• Routinematig genetisch testen op DM2 wordt niet aanbevolen bij patiënten met 
verdenking op FMS.
• Routinematige screening van CK en TSH wordt niet aanbevolen bij patiënten met 
verdenking op FMS in de tweede lijn, want abnormale waarden van CK en TSH zijn 
zeldzaam en resulteren niet in een alternatieve diagnose. 
• Pijn is een frequent en belangrijk symptoom bij patiënten met DM2 met een associatie 
tussen pijn en een slechtere kwaliteit van leven.
• Perifere mechanismen lijken een rol te spelen in de pathofysiologie van pijn bij patiënten 
met DM2.
• De rol van centrale sensitisatie van pijn bij patiënten met DM2 blijft onduidelijk, meer 
onderzoek is nodig. 
• Gastro-intestinale symptomen komen vaak voor bij patiënten met DM2, de meeste 
voorkomende zijn dysfagie, buikpijn en obstipatie.
• Een milde dysfagie komt regelmatig voor bij patiënten met DM2, deze leidt niet tot een 
aspiratiepneumonie of ondergewicht. 
• Perceptief gehoorverlies is een veel voorkomend symptoom bij patiënten met DM2, 
gelijkend op vervroegde presbyacusis. 
• DM2 blijft een uitdagende diagnose vanwege het enorme brede scala aan mogelijke 
symptomen en het zeer heterogene fenotype.
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Allereerst wil ik graag alle patiënten bedanken die mee hebben gedaan aan de onderzoeken. 
Jullie zijn de inspiratie geweest om dit onderzoek te starten. Zonder jullie was dit proefschrift 
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te kunnen doen.
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proefschrift geleid. Alle drie bedank ik jullie graag voor jullie (vrije) tijd en inzet om dit mogelijk 
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onze afspraken. 
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zeldzame ziekte, geen onderzoekstijd of onderzoeksgeld. Gaandeweg werden we een steeds 
beter team. Bedankt voor de ruimte die je me hebt geboden, en ook voor je vermogen om me 
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voor het includeren van de vele patiënten met fibromyalgie. Hans Scheffer, bedankt voor je 
bijdrage in onze brainstormavonden en het fibromyalgieproject. Hans Timmermans, bedankt 
voor je lessen in QST-metingen en het heen-en-weer gesjouw van het QST-apparaat. Chers 
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Après un debut un peu raide, notre étude sur l’audition a donné de très bons résultats.
Beste Jacqueline. Dankzij jou ben ik naast onderzoeker ook een halve accountant geworden. 
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om extra te komen werken voor de QST-metingen. Jan (Meulstee), naast je betrokkenheid 
in het gehoorproject wil ik je graag bedanken voor de wijze KNF-lessen tijdens mijn 
opleiding. Ook het secretariaat neurologie in het CWZ wil ik graag bedanken voor alle hulp 
en ondersteuning.
Alle oud-collega’s in het CWZ, bedankt voor de geslaagde opleidingsjaren, waarin er naast 
een fijne samenwerking en collegialiteit ook veel ruimte was voor humor en persoonlijke 
interesse. Lieve Xenia, Frouke en Kristel, het grootste deel van onze opleiding hebben we 
samen gedaan en zonder jullie was dat een stuk minder leuk geweest. Bedankt voor de 
gezelligheid en serieuze gesprekken, binnen en buiten onze opleiding. 
Lieve Xenia. Heel wat uren brachten we samen door; samen in de co-groep, samen in 
opleiding en samen op de KNF. Inmiddels zijn we niet meer samen op de werkvloer, maar we 
kunnen elkaar nog steeds storen bij nacht en ontij over lastige casuïstiek. En ook daar buiten 
zien we elkaar regelmatig. Ik bewonder je nuchterheid, eerlijkheid en directheid, en ben blij 
dat jij op deze bijzondere dag naast me staat als paranimf. 
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voor jullie warme welkom, humor en collegialiteit. En natuurlijk voor de letterlijke ruimte die 
jullie me gegeven hebben om dit proefschrift af te kunnen ronden. Dennis en Marcel, jullie 
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en met waxinelichtjes, vuur, de grote Dalmuti en politieke discussies zullen we nog vele 
weekenden kunnen vullen, bedankt voor jullie gezelligheid. Gang 6, bedankt voor de 
onvergetelijke avonden en weekendjes, het wordt weer tijd voor een volgende! Met name 
Frank, Sandra, Ingrid en Sjoerd, Nijmo’s, bedankt voor de warme vriendschap en steun, in 
goede en in slechte tijden. Xenia, José, Nadine en aanverwanten, kernladies van de co-groep: 
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Lieve schoonfamilie, Harry en Nonnie, Coen en Marielle, Woy en Ilse, graag wil ik jullie 
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de uitbreiding van onze familie met Laura en Iris, en de kleine Stan en Mats.
Lieve pap en mam. Zelfstandigheid, zelfredzaamheid en verantwoordelijkheid hebben jullie 
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alle drie voorbestemd om zorgwatje te worden, en alle drie inmiddels (ook) ondernemer! 
Bedankt voor jullie onvoorwaardelijke liefde, warmte en steun. Ik kan alleen maar hopen dat 
ik in staat ben hetzelfde voor onze kinderen te doen.
‘Mama, wanneer ga je nou die moeilijke vragen beantwoorden?’ Lieve Mirre, Boet en Siem. Al 
voor jullie komst legde ik de eerste hand aan dit boekje, en nu is het dan eindelijk klaar. Dat 
betekent meer tijd voor knutselmiddagen, potjes pesten, sprookjes lezen, samen bakken en 
koken, ‘kuffelen’, verstoppertje spelen in de tuin, wandelen en kamperen! 
Lieve Bjorn. Volstrekt onhandig, twee ambitieuze dokters aan het hoofd van een jong gezin. 
Maar ik zou niet anders willen, want niemand begrijpt mij zoals jij dat doet. Jij schept orde 
in mijn chaos, trapt op de rem waar ik soms te veel wil en geeft me zelfvertrouwen waar mij 
dat soms ontbreekt. Bedankt voor je onvoorwaardelijke liefde en de geboden ruimte om dit 
proefschrift af te ronden. Ik hou van je! 
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DONDERS GRADUATE SCHOOL FOR COGNITIVE NEUROSCIENCE
For a successful research Institute, it is vital to train the next generation of young scientists. 
To achieve this goal, the Donders Institute for Brain, Cognition and Behaviour established the 
Donders Graduate School for Cognitive Neuroscience (DGCN), which was officially recognised 
as a national graduate school in 2009. The Graduate School covers training at both Master’s 
and PhD level and provides an excellent educational context fully aligned with the research 
programme of the Donders Institute. 
The school successfully attracts highly talented national and international students in 
biology, physics, psycholinguistics, psychology, behavioral science, medicine and related 
disciplines. Selective admission and assessment centers guarantee the enrolment of the 
best and most motivated students.
The DGCN tracks the career of PhD graduates carefully. More than 50% of PhD alumni show 
a continuation in academia with postdoc positions at top institutes worldwide, e.g. Stanford 
University, University of Oxford, University of Cambridge, UCL London, MPI Leipzig, Hanyang 
University in South Korea, NTNU Norway, University of Illinois, North Western University, 
Northeastern University in Boston, ETH Zürich, University of Vienna etc.
Positions outside academia spread among the following sectors: 
- specialists in a medical environment, mainly in genetics, geriatrics, psychiatry and neurology,
- specialists in a psychological environment, e.g. as specialist in neuropsychology, psychological 
diagnostics or therapy, 
- higher education as coordinators or lecturers. 
A smaller percentage enters business as research consultants, analysts or head of research 
and development. Fewer graduates stay in a research environment as lab coordinators, 
technical support or policy advisors. Upcoming possibilities are positions in the IT sector and 
management position in pharmaceutical industry. In general, the PhDs graduates almost 
invariably continue with high-quality positions that play an important role in our knowledge 
economy.
For more information on the DGCN as well as past and upcoming defenses please visit:
http://www.ru.nl/donders/graduate-school/phd/
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